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Summary 
 
Bacterial resistance against antibiotic treatments is a global concern and resistance to almost every 
known antibiotic has already been reported. There is thus a significant need for the development of 
novel antimicrobial drugs. 
 
In addition to probiotic traits, certain bacteria have the ability to produce antimicrobial peptides, 
referred to as bacteriocins. Lantibiotics, a group of small ribosomally synthesized bacteriocins, 
recently gained interest for their application in the medical field. Lantibiotics have a very specific 
structure, including lanthionine rings, that stabilise the peptides. Due to their small size and specific 
action, these peptides reach specific sites of infection without affecting the composition of the host’s 
natural microbiota. As with any therapeutic agent, antimicrobial peptides are also prone to in vivo 
degradation, binding, clearance via immune action and development of bacterial resistance. 
 
Nisin F, a class Ia lantibiotic produced by Lactococcus lactis subsp. lactis F10, has already shown 
activity against the well-known pathogens Stapylococcus aureus, Listeria monocytogenes and various 
antibiotic resistant strains. The aim of this study was to assess the antimicrobial activity of nisin F 
against systemic S. aureus infections in mice and possible immune responses elicited by the peptide. 
 
A single administration of nisin F to the peritoneal cavity protected mice from S. aureus infection for 
at least 15 min. After continuous administration, the peptide showed no significant antimicrobial 
activity against S. aureus. The peptide did, however, convey some degree of protection to infected 
mice by stimulating a pro-inflammatory action through lymphocyte protection. When administered to 
uninfected mice, nisin F had an immune boosting effect via interleukin (IL)-6 and IL-10 without 
being detrimental to the host. The ex vivo effects of nisin F was compared to nisin A, a natural nisin 
variant, and Nisaplin®, a commercially purified form of nisin A. None of the three peptides inhibited 
the functional capacity of leukocytes in terms of 1L-1β en IL-6 production,  not even in the presence 
of an external stimulus (lipopolysaccharides from Escherichia coli). Cytotoxicity was detected in 
response to high dosages of nisin F. Serum inhibited the antimicrobial effect of nisin F and nisin A, 
but Nisaplin® remained unaffected. 
 
Nisin F was applied against systemic infection for the first time and the immunological effect of the 
peptide was investigated. Nisin F partially protected mice against S. aureus infections through 
immunomodulatory effects. This study provided valuable knowledge on the in vivo application of 
nisin F. With further optimization of nisin F preparation and application systems, the peptide might be 
more effective against in vivo infections.  
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Opsomming 
 
Bakteriële weerstand teen antibiotika wek wêreldwyd kommer en weerstand teen amper elke bekende 
antibiotikum is reeds aangemeld. Daar is dus 'n groot behoefte vir die ontwikkeling van nuwe 
antimikrobiese middels. 
 
Bykomend tot probiotiese eienskappe, het sekere bakterieë die vermoë om antimikrobiese peptiede, 
bekend as bakteriosiene, te produseer. ‘n Groep klein ribosomaal-gesintetiseerde bakteriosiene, 
lantibitiotika, is onlangs vir mediese toepassing oorweeg. Lantibiotika beskik oor 'n baie spesifieke 
struktuur, insluitend lantionien ringstrukture, wat die peptied stabiliseer. Weens hul klein grootte en 
spesifieke aksie is hierdie peptiede daartoe in staat om spesifieke areas van infeksie te bereik sonder 
om die gasheer se natuurlike mikrobepopulasie te beïnvloed. Soos met enige terapeutiese middel, is 
bakteriosiene ook geneig tot in vivo afbreking, binding, klaring via die immuunsisteem en 
ontwikkeling van bakteriële weerstand. 
 
Nisien F, 'n klas Ia lantibiotikum, deur Lactococcus lactis subsp. lactis F10 geproduseer, het reeds 
aktiwiteit teen die bekende patogene Stapylococcus aureus, Listeria monocytogenes en verskeie 
antibiotika-weerstandige stamme getoon. Die doel van hierdie studie was om die antimikrobiese 
aktiwiteit van nisien F teen sistemiese S. aureus infeksies in muise te bepaal, asook die  moontlike 
immuunreaksies wat die peptied mag veroorsaak. 
 
'n Enkele toediening van nisien F het muise vir ten minste 15 min teen S. aureus beskerm. Na 
deurlopende administrasie het die peptied geen beduidende antimikrobiese aktiwiteit teen S. aureus 
getoon nie. Die peptied het egter 'n mate van beskerming aan geinfekteerde muise verleen deur ‘n pro-
inflammatoriese aksie te inisieer deur limfosiet beskerming. Met toediening aan gesonde diere, het 
nisien F 'n immuunversterkende effek teweeg gebring via interleukin (IL)-6 en IL-10 vlakke, sonder 
nadelige uitwerking op die gasheer. Die ex vivo effek van nisien F is ook vergelyk met nisien A, 'n 
natuurlike variant van nisien, asook Nisaplin®, 'n kommersieël-gesuiwerde vorm van nisien A. Nie 
een van die drie peptide het leukosiete se funksionele kapasiteit in terme van 1L-1β en IL-6 produksie 
inhibeer nie, selfs nie in die teenwoordigheid van ‘n eksterne stimulus (lipopolisakkariede van 
Escherichia coli) nie. Seltoksisiteit is na blootstelling aan hoë dosisse van nisien F waargeneem. 
Serum het die antimikrobiese effek van beide nisien F en nisien A geïnhibeer, terwyl die werking van 
Nisaplin® nie beïnvloed is nie. 
 
Nisien F is  vir die eerste keer teen sistemiese infeksies ingespan en die immunologiese impak van die 
peptied is ondersoek. Nisien F het gedeeltelike beskerming aan muise met S. aureus infeksies verleen 
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deur die immuunsisteem te versterk. Die resultate het ‘n waardevolle bydrae gelewer tot die in vivo 
toediening van nisien F. Met verdere optimisering van nisien F voorbereiding en toedieningsisteme, 
mag die peptied moontlik meer effektief teen in vivo infeksies aangewend word.  
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Preface 
 
This thesis is presented as a compilation of manuscripts. Each chapter is introduced separately and is 
written according to the style of the respective journal. Two articles have been published and two 
manuscripts have been prepared for submission to ISI-accredited journals. All other chapters have 
been written according to the instructions of the Journal of Applied Microbiology. 
 
The literature review is an overview of global and South African occurrence of antimicrobial 
resistance and description of Staphylococcus aureus, one of the most prevalent organisms in this 
regard. The biosynthesis, mode of action, in vivo monitoring and application of bacteriocins, with the 
focus on nisin, are also discussed.  
 
The manuscript “Development of a murine model with optimal routes for bacterial infection and 
treatment, as determined with bioluminescent imaging in C57BL/6 mice” has been published in 
Probiotics and Antimicrobial Proteins (2011; 3, 125-131) and is presented in Chapter 3 as published. 
 
The manuscript “The ability of nisin F to control Staphylococcus aureus infection in the peritoneal 
cavity, as studied in mice” has been published in Letters in Applied Microbiology (2010; 51, 645-649) 
and is presented in Chapter 4 as published. 
 
The manuscript “The effects of continuous in vivo administration of nisin F on Staphylococcus aureus 
infection and immune response in mice” has been prepared for submission to International Journal of 
Antimicrobial Agents and is presented in Chapter 5. 
 
The manuscript “Antimicrobial activity of nisin F, nisin A and Nisaplin in the presence of serum and 
the effect of these lantibiotics on leukocyte functional capacity” has been prepared for submission to 
Journal of Peptide Science and is presented in Chapter 6. 
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Introduction 
 
Antimicrobial resistance is a serious problem, also in Africa (Okeke and Sosa 2003). The infectious 
disease burden in Africa is high and financial constraints prevent proper distribution and 
implementation of the latest and more expensive antibiotics. The situation is further worsened by poor 
sanitation and general hygiene, over-population, food-animal husbandry and the abuse of antibiotics. 
Although the World Health Organization (WHO) implemented a global strategy in 2001 to control 
antimicrobial resistance, developing regions such as Africa seems to be worse-off (WHO 2001; 
Nyasulu et al. 2012).  
 
Staphylococcus aureus is an opportunistic pathogen with asymptomatic colonization of epithelial and 
mucosal surfaces. Apart from being one of the most important hospital-associated pathogens, infection 
can lead to minor skin diseases and invasive diseases such as bacteraemia, endocarditis and toxic 
shock syndrome (Lowy 1998; Diekema et al. 2001; Daum 2008). Wounds originating from implants, 
prosthetic devices or damaged skin create the perfect environment for infection. Before the 
introduction of antimicrobials, 90% of invasive S. aureus infections led to death. Penicillin was 
initially used as treatment, but certain strains soon developed resistance to the antibiotic (Barber 
Rozwadowska-Dowzenko 1948), including other popular antibiotics such as methicillin (Jevons 1961) 
and vancomycin (Moran and Mount 2003). Resistance was also recorded against newly applied 
antibiotics such as the quinopriston and dalfopristin combination (Luh et al. 2000, Deshpande et al. 
2004) and linezolid (Gonzales et al. 2001; Kola et al. 2007). Methicillin-resistant S. aureus (MRSA) is 
often multi-drug resistant and continues to raise concerns with its rapid spreading into health and 
community settings around the globe (Stefani et al. 2012).  
 
In 2008, approximately 90 000 invasive MRSA infections were recorded in the United States. Of these 
cases, 15 249 patients died while hospitalized (CDC 2008). According to a study done in 2005, 85% of 
all invasive MRSA infections were healthcare-associated, with two-thirds reported to have occurred 
outside the hospital (CDC 2007). Cases recorded were from diverse geographical areas, but were more 
prominent in people older than 65 years, Blacks and males. In South Africa, MRSA isolates from 
various hospitals and private laboratories showed high-level multi-drug resistance (Marais et al. 2009). 
Resistance to the macrolides, tetracycline and the aminoglycosides were observed, while vancomycin, 
linezolid and quinopristin/dalfopristin seemed appropriate agents for clinical use in South Africa 
(Marais et al. 2009; Nyasulu et al. 2012). Resistance patterns varied between children and adults, and 
between public and private systems. With a study conducted in Cape Town, South Africa, two 
rifampicin-resistant MRSA strains were isolated (Van Rensburg et al. 2012). Global antibiotic 
resistance against vancomycin (VRSA: Vancomycin-resistant S. aureus) and the recently applied 
antibiotics daptomycin and linezolid (Sakoulas and Moellering 2008) poses a great challenge to and 
need for the development of alternative treatments for S. aureus infections.  
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Lactic acid bacteria (LAB) have the ability to produce small antimicrobial peptides (AMPs) called 
bacteriocins - lately extensively studied for their therapeutic properties. Due to their generally 
regarded as safe (GRAS) status, small size, specific binding sites, mode of action, and ability to act in 
nanomolar concentrations, class I bacteriocins are continuing to become more appealing than 
conventional antibiotics. Nisin F is a class IIa bacteriocin with in vitro antimicrobial activity against S. 
aureus (De Kwaadsteniet et al. 2008). Although not successful in in vivo antimicrobial treatment, nisin 
F showed no abnormal side-effects when tested against respiratory S. aureus infections in rats and 
subcutaneous S. aureus skin infections in mice (De Kwaadsteniet et al. 2009, 2010). Nisin F 
successfully cured subcutaneous S. aureus infections in mice when incorporated into bone cement 
(Van Staden et al. 2012).  
 
Bioluminescent imaging (BLI) is a recently explored process that allows researchers to track bacterial 
and viral infection, gene expression, protein stability and tumour growth in small animals (Contag et 
al. 1995; Prescher and Contag 2010). The BLI technique is based on the capturing and quantification 
of visible light produced by luciferase reactions. In this study BLI was implemented to monitor the 
therapeutic effect of nisin F. 
 
Drug discovery and development take several years and involve a few critical steps. The drug should 
not only exert in vitro, but also in vivo activity. Usually in vivo pre-clinical studies are carried out on 
small mammals such as rodents, and when successful, progress to larger mammals and human clinical 
trials. Results obtained through ex vivo studies on a drug, e.g. toxicity to eukaryotic cells or 
immunomodulatory properties, often add valuable information to knowledge gained from in vitro and 
in vivo studies. 
 
The objectives for this study were: 
 to optimize in vivo infection of S. aureus and optimize treatment dosages of nisin F;  
 to determine the ability of a single administration of nisin F to control S. aureus infection in 
the peritoneal cavity, as studied in mice; 
 to determine the antimicrobial ability of continuous administration of nisin F to control S. 
aureus infection in the peritoneal cavity of mice; and 
 to determine the immunological effect and stability of nisin F in ex vivo studies.  
 
Thus, the final outcome of the study was to gain more information on the stability of nisin F in vivo 
and to serve as a stepping stone in the process of developing nisin F as an anti-staphylococcal drug. 
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Literature Review 
 
1. Antimicrobial resistance  
The discovery of penicillin by Fleming in 1928 brought a dramatic revolution in medicine and created 
the belief that antibiotics will cure all infectious diseases (Fleming 1928). Soon, pathogenic 
microorganisms started to develop resistance to penicillin and other antibiotics that were subsequently 
developed. Today, resistance to almost every known antibiotic has been reported. Clinical isolates use 
different mechanisms to acquire resistance to antibiotics. These may include alterations of the 
target/binding site of the agent, modification of the agent, or restricting intracellular access of the 
agent (Konings et al. 2000). Factors influencing antimicrobial resistance (AMR) include inappropriate 
prescription and use of antibiotics, mobility of humans or animals, antibiotics used in food production 
and animal husbandry, as well as contaminated water and soil sources. 
 
According to the World Health Organisation (WHO), AMR is still a world-wide crisis (2012). 
Although a global strategy was implemented in 2001, AMR is increasing morbidity and mortality rates 
(especially resistance to malaria, tuberculosis, HIV and common bacterial diseases) in healthcare 
facilities and communities. In 2009, the annual number of deaths in Europe caused by resistant 
pathogens exceeded 25 000, with MRSA responsible for 5 400 (37%) of the mortalities and more than 
a million additional hospitalisation days of patients (ECDC/EMEA 2009). Thus, AMR also has a 
negative economic impact. A patient infected with a resistant strain has to undergo more diagnostic 
testing, receive treatment with second-line antibiotics, and may even have to be hospitalized for a 
longer period.  This leads to an increased possibility for the resistant strain to spread, or for the patient 
to acquire secondary infections (Wenzel and Edmond 2000; Laxminarayan 2003). In 1999, a full 
course of treatment for multidrug-resistant tuberculosis (TB) would have cost a patient R26 354, 
versus R215 for treatment of infection with a susceptible TB strain (Hensher 1999). 
 
It is essential to assess the level of AMR in a country to put the necessary precautions in place. A few 
surveillance attempts were carried out by the South African Society of Clinical Microbiology, 
formerly known as the National Antimicrobial Surveillance Forum (NASF), as well as the Group for 
Enteric, Respiratory and Meningeal Diseases Surveillance (GERMS-SA), amongst others. Recently, 
an AMR surveillance program was initiated in South Africa by the Global Antibiotic Resistance 
Partnership (GARP) of the Centre for Disease Dynamics, Economics and Policy (CDDEP). Although 
of value, a standard surveillance program is still lacking (Nyasulu et al. 2012). Results from previous 
surveillance studies revealed that Klebsiella pneumonia, Escherichia coli, Pseudomonas aeruginosa 
and Staphylococcus aureus are the most resistant nosocomial pathogens (Apalata et al. 2011; Nyasulu 
et al. 2012). In a systematic review of nine AMR studies done in South Africa, Nyasulu et al. (2012) 
summarized antibiotic resistant S. aureus strains from clinical origin. On average, 38% of tested S. 
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aureus strains were resistant to erythromycin, while no resistance to vancomycin or linezolid were 
observed (Fig. 1). 
 
 
Figure 1 Antibitiotic resistance patterns amongst strains of S. aureus isolated from patients in South 
African clinics (adapted from Nyasulu et al. 2012). 
 
2. Staphylococcus aureus 
Staphylococcus aureus is a member of the Staphylococcaceae family and is characterized by Gram-
positive clusters of microcapsulated, nonsporulating, nonmotile cocci (Lowy 1998). The golden 
yellow colonies ferment mannitol (Gould and Chamberlain 1995) and flourish in saline conditions, as 
normally found on the skin surface (Thomas 1988).  Staphylococcus  aureus is a facultative anaerobe 
that grows between 15 and 45˚C, withstand high NaCl concentrations and drying (Matouskova and 
Janout 2008), and is catalase and coagulase positive.  
 
Staphylococcus aureus became resistant to penicillin in the late 1940s to mid-1950s, with hospitals 
reporting 50% of all strains resistant (Barber and Rozwadowska-Dowzenko 1948; Colebrooke 1955). 
Strain 80/81, the first penicillin-resistant strain, originated in Australia and was transferred to America 
and the UK (Williams et al. 1959). The arrival of the semi-synthetic penicillin, methicillin, led to a 
decrease in cases of 80/81 infection (Matouskova and Janout 2008). Within six months, methicillin-
resistant strains that originated were detected in England (Jevons 1961) and were classified as 
hospital-acquired methicillin resistant Staphylococcus aureus (HA-MRSA). These strains are also 
resistant to the antibiotics cloxacillin, fluocloxacillin and cephalosporins used before methicillin 
(Gould and Chamberlain 1995). Multidrug-resistant MRSA strains with combined resistance to 
peniciliin, streptomycin, tetracycline and erythromycin were reported in 1971 (Grundmann et al. 
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2006). During the 1970s and early 1980s, the prevalence of multidrug-resistant MRSA strains 
decreased only to be followed by an increase in the 1980s and 1990s with outbreaks that lasted just 
more than two years (Tuffnell et al. 1987). Gentamycin resistance was detected in strains at the start of 
the eighties. A healthcare worker (HCW) transferred the strain from Australia to England (Duckworth 
et al. 1988). Vancomycin resistance emerged in 1987 (Scwalbe 1987), increased from 1996 
(Hiramatsu et al. 1997) and a fully-resistant strain was isolated from a patient in Michigan in 2002 
(CDC 2002). Staphylococcus aureus strains with intermediate susceptibility to vancomycin (VISA), 
heterogeneous VISA (hVISA) and linezolid-resistant S. aureus (LRSA) strains have been isolated, as 
well as MRSA isolates with decreased glycopeptide susceptibility (glycopeptide intermediately 
susceptible S. aureus, GISA). Isolates that spread globally were termed epidemic MRSA (EMRSA), 
opposed to methicillin-susceptible S. aureus (MSSA). 
 
Community-acquired methicillin-resistant S. aureus (CA-MRSA) has become more prevalent in the 
last two decades (CDC 1999). Infections with CA-MRSA are classified according to certain criteria. 
Firstly, the diagnosis should be made outside of a hospital or within 48h after admission to a hospital. 
Secondly, the patient should not have any medical history of MRSA before or after admission to the 
hospital and finally, the patient should not have any internal catheters or medical devices (CDC 2005). 
CA-MRSA infections usually occur in young individuals by means of skin and soft tissue infections 
(SSTIs) (Table 1).  
 
Table 1 Main characteristics of HA-MRSA and CA-MRSA strains (Matouskova and Janout 2008) 
Characteristic HA-MRSA CA-MRSA 
Clinical surgical site infections, invasive skin infections, “bug bites”, rarely 
invasive, multiple, recurrent 
Epidemiology Age, healthcare young, athletes, drug users, 
correctional facilities and military 
 
Antibiotic resistance multi-drug resistant  β-lactam resistant 
Molecular markers PVL – 
SCCmec I-III 
PVL + 
SCCmec IV, V 
 
Panton-Valentine leukocidin (PVL) is a toxin and virulence factor lethal to neutrophils. It causes tissue 
necrosis by forming heptameric pores in leukocyte membranes and is associated with CA-MRSA, 
SSTIs (Lina et al. 1999) and severe necrotizing pneumonia (Labandera-Rey et al. 2007). CA-MRSA 
strains are β-lactam resistant, PVL+ and possess SSCmec types IV or V. HA-MRSA are more 
prevalent in older individuals in hospital or healthcare facilities, are multidrug-resistant, PVL- and 
possess SSCmec types I-III (Matouskova and Janout 2008). Differentiating between HA-MRSA and 
CA-MRSA based on epidemiological aspects is becoming more difficult due to multiple definitions, 
the rapidly changing molecular features of CA-MRSA and the adaptation to transmission within 
hospitals and healthcare-facilities by certain strains, e.g. US300 (David et al. 2008). In addition, 
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infection acquired in the community can be transmitted in the hospital and vice versa (Flynn and Scott 
2008). HA-MRSA infections can be sub-classified into hospital-onset (positive culture obtained more 
than 48h after admission) or community-onset (positive culture obtained less than 48h after admission) 
(Klevens et al. 2007). 
 
2.1 Prevalence 
Humans are a natural reservoir of S. aureus with asymptomatic colonization primarily in the anterior 
nares of the nose and on the skin (Williams 1963; Peacock et al. 2001). In hospitals, patients are 
regarded as the main reservoirs with doctors and nurses as carriers (Gould and Chamberlain 1995). In 
severe CA-MRSA cases, colonization was also detected in areas of the axillae, inguinal and rectum 
(Decker 2008). Colonization occurs more often in males (Ayliffe et al. 1977), especially those who 
have homosexual intercourse (Diep et al. 2008). Intravenous drug users, patients who underwent 
hemodialysis or surgery and individuals with type 1 diabetes, acquired immunodeficiency syndrome 
(AIDS), or leukocyte malfunction are more prone to colonization and subsequent S. aureus infection 
(Lowy 1998). Furthermore, foreign material used in invasive therapy, such as intravenous catheters, 
intubation or ventilation also increases the risk of infection (Gould and Chamberlain 1995; Lowy 
1998). Older people often receive surgery and orthopaedic implantations, which places them into a 
high-risk category (Ayliffe et al. 1977). While the control of MRSA in long-term care facilities and 
nursing homes are increasing, only a few studies have been done on these settings (Navarro et al. 
2008). Transmission usually occurs via skin contact with health workers or less frequently from 
environmental vectors. Athletes are often infected by CA-MRSA from contaminated objects (e.g. 
shared razors, soap bars, towels), whirlpools and damaged skin (Begier et al. 2004; Kazakova et al. 
2005). Contaminated stethoscopes (Smith et al. 1996), pagers (Singh et al. 2002), workstations and 
bed sites (Hardy et al. 2006) can also spread infection. Airborne transmission occurs only across 
distances of a few feet (Gould and Chamberlain 1995). Domesticated animals may also spread MRSA 
to humans when in close contact with them or eating contaminated meat products (Navarro et al. 2008; 
Matouskova and Janout 2008). 
 
2.2 Infection  
Human infections occur often, but mostly stay localized at the site of entry due to the host defences. 
Staphylococcus aureus infection can lead to minor SSTIs, abnormalities such as boils, styes and 
furuncles. More serious diseases caused by S. aureus include bacteraemia, sepsis, mastitis, toxic shock 
syndrome, endocarditis and metastatic infections which spread to the bones (osteomyelitis), joints 
(arthritis), kidneys, lungs, heart and skeletal muscle (Lowy 1998; Todar). Outbreaks in hospitals are 
also associated with discharging wounds, urinary tract infections, otitis media, pneumonia (Gould and 
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Chamberlain 1995), skin lesions and erythema (Navarro et al. 2008). Staphylococcus aureus also 
causes food poisoning. A summary of diseases caused by S. aureus is shown in Fig. 2. 
 
 
Figure 2 Diseases caused by Staphylococcus aureus (adapted from Arbuthnott et al. 1990). 
 
Exterior signs of infection usually include increased temperatures at the site of infection, formation of 
pus and necrosis of tissue. Fibrin causes blood clotting around the area, preventing bacteria from 
spreading. Staphylococcus aureus attaches to host proteins such as laminin and fibronectin with the 
Release of 
extracellular 
products 
Bacteraemia 
(asymptomatic 
acute) 
 
Skin 
Nasopharynx 
Eyes 
Gastraintestinal tract (G.I.T.) 
Urethra 
Vagina 
Skin: carbuncles, furuncles, 
subcutaneous absecesses 
Nasopharynx: sinusitis, tonsillitis, 
glandular infections 
Eyes: deep orbital infections 
G.I.T.: food poisoning 
Urethra: cystitis, prostatitis 
Vagina: cervicitus, salpingitis, 
pelvic infection 
Contiguous infections Symptomatic 
colonization or local 
infections 
Bones, joints: osteomyelitis, arthritis 
Lungs: pneumonia 
Muscle: abscesses 
Heart: endocarditis 
Abdominal organs: abscesses 
Central nervous system: cerebritis, meningitis, brain 
abscesses 
Metastatic sites 
of infection 
Staphylococcal scalded skin syndrome 
Food poisoning 
Toxic shock syndrome 
Toxin-mediated syndromes 
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help of surface proteins it produces. It also produces a fibrin or fibrinogen binding protein, referred to 
as a clumping factor (Todar 2009).  
 
The mode of S. aureus infection is illustrated in Fig. 3 (Lowy 1998). Circulating staphylococci bind to 
sites of endovascular damage where platelet–fibrin thrombi (PFT) have formed. Bacterial adhesion 
can take place through MSCRAMM-mediated mechanisms, through endothelial cells via adhesin–
receptor interactions, or via bridging ligands such as  fibrinogen. The bacteria produce proteolytic 
enzymes that facilitate the spread to nearby tissues after phagocytosis by endothelial cells. This is 
followed by the release of staphylococci into the bloodstream. Endothelial cells express the tissue 
factor that facilitates the deposition of fibrin and the formation of vegetations. An inflammatory 
response occurs once the infection has spread to the adjoining sub-epithelial tissues, leading to abscess 
formation. After phagocytosis, endothelial cells express Fc receptors, adhesion molecules [vascular-
cell adhesion molecules (VCAM)] and intercellular adhesion molecules (ICAM), and release 
interleukin-1, interleukin-6, and interleukin-8. As a result, leukocytes adhere to endothelial cells, with 
diapedesis to the site of infection.  
 
Changes in the conformation of endothelial cells result in increased vascular permeability, with 
transudation of plasma proteins. Both tissue-based macrophages and circulating monocytes release 
interleukin-1, interleukin-6, interleukin-8, and tumor necrosis factor a (TNF-a) after exposure to 
staphylococci. Macrophage activation occurs after the release of interferon-g by T cells. Cytokines 
released into the bloodstream from monocytes or macrophages and endothelial cells, contribute to the 
manifestation of the sepsis syndrome and vasculitis associated with systemic staphylococcal disease. 
Expression of Fc receptors may contribute to vasculitis occasionally encountered during bacteremia by 
acting as a binding site for immunoglobulin (Ig) or immune complexes.  
 
 
Figure 3 Mechanism of infection (from Lowy 1998). PMN denotes polymorphonuclear leukocyte. 
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2.3 Virulence  
Staphylococcus aureus expresses a wide variety of virulence factors. Colonization of host tissues is 
aided by surface proteins and the spread of infection by invasins such as leukocidin, kinases, and 
hyaluronidase. Phagocytic engulfment are prohibited by surface factors including capsules and Protein 
A, but once inside phagocytes, these bacteria produces carotenoids and catalases to survive. Protein A 
and coagulase act as immunological disguises. Eukaryotic cell membranes are lysed by toxins such as 
hemolysins, leukotoxin and leukocidin. Staphylococcus aureus also produces exotoxins (SEA-G, 
TSST and ET), which damages host tissues or provoke symptoms of disease. Inherent and acquired 
antimicrobial resistance form a very important part of the virulence of S. aureus.  
 
The staphylococcal genome consists of a circular chromosome (of approximately 2.8 Mbp), with 
prophages, plasmids and transposons. Genes encoding antibiotic resistance (Table 2) and virulence are 
transferred between species and strains through extrachromosomal elements including plasmids (Lowy 
1998). Approximately 75% of the S. aureus genome is conserved between strains and is referred to as 
the ‘core’ genome. The remaining 25%, the ‘accessory’ genome, consists of mobile genetic elements 
(MGEs) providing virulence and resistance (El Garch et al. 2009). Little is known about the bacterial 
and host factors that promote S. aureus colonization (Foster 2004). Adaptations to the external 
environment (Wilson and Salyers 2003) and lateral gene transfer (Boyd and Brüssow 2002; Fitzgerald 
et al. 2001) between strains are partly responsible for evolution of pathogens.  
 
Table 2 Genes involved in antibiotic resistance 
 
Expression of virulence-associated proteins is controlled by the regulatory operons, agr (Kornblum et 
al. 1990), sar (Cheung et al. 1992), xpr (Smeltzer et al. 1993) and sae (Giraudo et al. 1994). The 
accessory gene regulator (agr) is the most important (Sabersheikh and Saunders 2004) among the 
above mentioned and varies between group I, II, III and IV (Diep et al. 2006). Staphylococcus areus 
agr specificity groups are classified as follows: strains causing invasive infections such as bacteraemia 
in group I, endocarditis strains in group II, menstrual toxic shock strains in group III and exfoliatin-
Gene Product Resistance to Reference 
bla β-lactamase penicillin  Lowy 1998 
fem factors essential for methicillin 
resistance 
methicillin Lowy 1998 
mecA PBP2 penicillin Matouskova and Janout 2008 
lukS-PV   Matouskova and Janout 2008 
lukF-PV   Matouskova and Janout 2008 
qacA and qacB  antiseptics Matouskova and Janout 2008 
vanA  vancomycin + teicoplanin Matouskova and Janout 2008 
vanB   vancomycin only Matouskova and Janout 2008 
vanC + vanC-like 
phenotype 
  Matouskova and Janout 2008 
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producing strains in group IV (Ji et al. 1997; Jarraud et al. 2000; Ben et al. 2006). Staphylococcus 
aureus has various virulence factors, including surface proteins that facilitate adhesion to damaged 
tissue, eliminate host immune responses in the blood (Foster 1998) and promote iron uptake 
(Mazmanian, 2003). Host immune responses are affected by the lysis of white blood cells by the 
leukotoxin Panton-Valentine Leukocidin (PVL), superantigens (TSST) or prevention of the migration 
of white blood cells (WBCs) to the infected site by the chemotaxis-inhibiting protein (CHIP) (de Haas 
et al. 2004). Bacterial proteins with superantigen activity which leads to overstimulation of cytokine 
release, include staphylococcal enterotoxins A–E, G–R and U (encoded by the genes sea– see, seg–ser 
and seu), toxic shock syndrome toxin-1 (TSST-1, encoded by tst), exfoliative toxins A and B (eta and 
etb) and other toxins such as α-, β-, γ- and δ-toxin and the leukotoxins, Panton–Valentine leukocidin 
(pvl) and leukocidin E-D (lukE-D) (Arbuthnott et al. 1982; Bhakdi and Tranum-Jensen 1991; Bohach 
et al. 1990; Prevost et al. 1995). Mertz et al. (2007) observed that the amount of WBCs in a specific 
area of tissue is directly related to the type of strain infecting the area. Strains able to produce ETA 
and ETB would more likely infect WBC-poor areas and PVL-positive strains will infect areas with 
more WBCs (Mertz et al. 2007). Surface proteins are predominantly synthesized during the 
exponential growth phase and the secreted proteins during the stationary phase (Lowy 1998). Surface 
proteins are more dominant during colonization whereas secreted proteins feature during persistence 
(Novick 1993). 
 
Staphylococcus aureus produces various toxins that target membranes of mammalian cells and cause 
tissue damage (Bohach et al. 1999). Superantigen toxins are responsible for diseases such as septic 
shock (Bohach et al. 1999). Enzymes such as hyaluronidase, lipase, staphylokinase, phospholipase, 
DNase, phosphatase and protease are secreted to destroy tissue (Arbuthnott et al. 1990; Lowy 1998). 
Other enzymes include coagulase and haemolysin that catalyse the conversion of soluble to insoluble 
fibrin. This in turn leads to blood clotting that surrounds the bacteria and protect them from host 
immune responses (Gould and Chamberlain 1995). Some virulence factors are encoded by genes 
situated on mobile genetic elements (e.g. TSST-1), pathogenicity islands, lysogenic bacteriophages 
(e.g. PVL) (Novick 2003) or genes integrated in the chromosome (de Haas et al. 2004). The 
horizontally transferred mecA gene is situated on the Staphylococcal Cassette Chromosome mec 
(SCCmec) and confers resistance to methicillin and other β-lactam antibiotics. Other resistance genes 
include bla (β-lactamase) and fem (factors essential for methicillin resistance). The SCCmec element 
integrates into the S. aureus chromosome at the attBscc site (Ito et al. 1999). This integration is 
facilitated by the invertase/resolvase family encoded by the ccr gene complex consisting of ccrA-C 
(Ito et al. 2003). The mecA gene encodes the 78-kDa penicillin-binding protein PBP2a or PBP. Five 
SCCmec (types I–V) have been characterized. Type I emerged in 1961 in the UK, type II in 1982 from 
Japan, type III in 1985 from New Zealand, type IV in 1990s and type V after 2000 from Australia 
(Hiramatsu et al. 2001; Ma et al. 2002; Ito et al. 2004). Several variants of these SCCmec types have 
been described. Three tentative types have recently been discovered - type VI (Oliveira et al. 2006), 
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type VII (Berglund et al. 2008) and type VIII (Zhang et al. 2009). The level of antibiotic resistance 
depends on the expression of related genes, the degree of expression and the presence of additional 
virulence genes (Peacock et al. 2002). 
 
The most common staphylococcal proteins anchored in the cell wall are proteins with affinity to 
fibrinogen (i.e. clumping factors A and B, encoded by the clfA and clfB genes, respectively), 
fibronectin (fnbA), collagen (cna), sialoprotein (bbp), elastin (ebpS) and adhesins with unknown 
function (sdrC and sdrE) (Speziale et al. 1986; Jonsson et al. 1991; Park et al. 1996; McDevitt et al. 
1997; Josefsson et al. 1998; Nı´ et al. 1998; Tung et al. 2000). Phenol-soluble modulin peptides, a new 
class of staphylococcal peptides, is associated with virulence of CA-MRSA skin infections. These 
peptides attack the main host defence response against S. aureus through lysis of neutrophils (Wang 
and Barret 2007). 
 
Virulence factors can act in combination, e.g. exfoliative and pyrogenic toxin superantigen production 
leads to staphylococcal scalded skin syndrome (SSSS), toxic shock syndrome (TSS) and food 
poisoning (Sauer et al. 2008). Some genes tend to associate with others, e.g. seg and sei (Jarraud et al. 
1999; Becker et al. 2003; El-Huneidi et al. 2006; Sauer et al. 2008) as well as sej and sed (Becker et al. 
2003; Mendoza and Martin 2005). Certain genes are also associated with specific diseases, e.g. PVL 
production with skin diseases such as furuncles, carbuncles and necrotizing pneumonia (Lina et al. 
1999), TSST-1 with septic shock and TSS (Uchiyama et al. 1989) and SSSS-causing isolates often 
express exfoliative toxins, ETA and ETB (Opal et al. 1988). The IL4 _524 C/C host genotype is 
associated with an increased probability of nasal S. aureus colonization, irrespective of the strain’s 
genotype. Persistent nasal colonization is associated with both the IL4 _524 C/C genotype and certain 
S. aureus AFLP strain markers, signifying the complexity of host-microbe interaction (Emonts et al. 
2008). 
 
2.4 Treatment 
2.4.1 CA-MRSA 
CA-MRSA strains are spreading fast into newly established residential areas and are becoming more 
drug resistant, probably due to migration and travelling of individuals (Bartels et al. 2007). Aggressive 
control in these areas is practically impossible, but systematic topical decontamination of carriers 
remains an option (Navarro et al. 2008). Screening, contact tracing and decolonization of CA-MRSA 
carriers were also implimented in Denmark (Navarro et al. 2008). Vaccines have shown improved 
phagocytosis in vitro (Lowy 1998) and are currently in development for treatment of large 
communities (Wang and Barret 2007). However, according to the World Health Organization (WHO) 
prevention of S. aureus infections by vaccination remains challenging, especially regarding possible 
antigen development and ethical concerns among vaccinated patients. Vaccines developed against S. 
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aureus include StaphVAX, a polysaccharide conjugate vaccine (Fattom et al. 2004) and PentaStaphTM, 
a staphylococcal polysaccharide conjugate and toxoid vaccine (NABI Biopharmaceuticals). Prevention 
of CA-MRSA in hospitals is challenged by the constant emergence of new EMRSA strains (Otter and 
French 2006), rapid molecular changes (Kennedy et al. 2008) and difficulty in distinguishing between 
CA-MRSA and HA-MRSA (Maree et al. 2007). Since CA-MRSA is becoming more prevalent in 
hospital settings, HA-MRSA control techniques can also be implemented (Navarro et al. 2008). 
 
2.4.2 HA-MRSA 
Some hospitals implemented the technique of screening all patients upon admission, but delayed test 
results (4-5 days) compromised effective treatment. The majority of patients were infected in the 
hospital as a result of post-operative contamination or prolonged stay. The personal hygiene of HCWs 
continues to play an important role in preventing HA-MRSA infections. Alcoholic hand rubs has 
proven to be very effective (Johnson et al. 2005), although S. aureus has developed resistance to 
quaternary ammonium-type antiseptic compounds (Rouch et al. 1990; Bjorland et al. 2001). HCWs 
that frequently come into contact with colonized or infected patients should be regularly screened for 
the presence of MRSA (Siegel et al. 2007). Decolonization of patients by whole body bathing or 
eradication of the gastro-intestinal tract and wounds is another way of preventing MRSA infection in 
hospitals (Wendt et al. 2007). Systemic decolonization with mupirocin is also an option, but can lead 
to resistance (Vasquez et al. 2000). Infected patients can be cohorted in a single room where only 
certain HCWs treat these patients (Sexton et al. 2006).  
 
Decontamination of the hospital environment is also very important. Approximately 64-74% of all 
hospital surfaces including bedding, mattresses, door handles, grab bars and taps are contaminated. 
Equipment includes keyboards, pagers, stethoscopes, membranes of blood pressure gauge sleeves and 
tourniquets used in blood sampling (Oomaki et al. 2006; Dancer 2008). Antibiotics used in treatment 
are the semi-synthetic penicillin, oxacillin or nafcillin, vancomycin, daptomycin, quinopristin-
dalfopristin, rifampicin and ciprofloxacillin (Lowy 1998), teichoplanin (Gould and Chamberlain 1995) 
and various oxzolidinones. Linezoid and synercid are also relatively new drugs used (Foster 2004). 
Antibiotic resistance to the new drugs quinopristin-dalfopristin and tigecycine has already been 
reported (Peeters and Sarria 2005; Skiest 2006). Medical practitioners often use combinations of 
antimicrobials in an attempt to limit antimicrobial resistance. 
 
3. Antimicrobial peptides  
Antimicrobial peptides (AMPs) are produced by a variety of organisms including humans, insects, 
plants and bacteria. In addition to the host’s innate and acquired immune responses, AMPs are often 
incorporated in response to pathogenic invasion (Reddy et al. 2004). Most AMPs are small (<10 kDa), 
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cationic, hydrophobic proteins with antibacterial, antifungal or antiviral activity (Bals 2000). Some 
AMPs have also shown anti-tumour (Bals 2000) and spermicidal (Reddy et al. 1996; Aranha et al. 
2004) activity. Certain AMPs administered in low concentrations also proved to diminish well-
established biofilms (bacterial populations protected by extracellular macromolecules) on surgically 
implanted medical devices (Upton et al. 2012). Biofilms on medical devices are often targets for 
secondary infections in the hosts due to their resistance to high levels of conventional antibiotics.  
 
The fact that AMPs are mostly active against specific groups of bacteria, indicate that they are less 
detrimental to the host’s natural flora. Their activity in a wide range of temperature and pH, specific 
mode of action and low toxicity to eukaryotic cells, render them favourable candidates for novel 
therapeutic agents. In general, AMPs can benefit the host in one of four ways: 1) to treat infection 
when administered alone, 2) to act synergistically when administered in combination with 
conventional antibiotics or antivirals, 3) to act as immunostimulators of the innate immune system, 
and 4) to neutralize endotoxins produced by pathogens (Gordon and Romanowski 2005).  
 
A few AMPs have been found to enhance the penetration of conventional antibiotics through the 
bacterial membrane of multidrug-resistant Pseudomonas aeruginosa when administered in 
combination with the antibiotic.  They include magainin II and cecropin A administered with 
rifampicin (Cirioni et al. 2008), tachyplesin III with imipenem (Cirioni et al. 2007), and P5 with 
isepamicin (Jeong et al. 2010). The synergistic effect allows lower dosages of the antibiotics (Barriere 
1992), as well as reduced resistance development in certain cases (Wu et al. 1999; Steenbergen et al. 
2009). A number of AMPs have been evaluated in clinical trials, but with limited success and with 
FDA-approval for topical application only (Gordon and Romanowski 2005; Park et al. 2011). They 
include omiganan/ MBI-226 for catheter-related local and bloodstream infection (Isaacson 2003; 
Rubinchik et al. 2009; Yeung et al. 2011), pexiganan/ MSI-78 for diabetic foot ulcers (Hancock and 
Sahl 2006), plectasin against drug-resistant bacteria (Hancock and Sahl 2006; Zaiou 2007), opebacan 
for endotoxemia in hematopoetic stem cell transplants (Zhang and Falla 2006; Yeung et al. 2011), 
iseganan/ IB-367 for oral mucositis (Hancock and Sahl 2006), MBI 594AN and XMP.629 for topical 
treatment of acne, P113 P113D mouthrinse for oral candidiasis in HIV patients, and neuprex/ rBPI21 
for systemic treatment of pediatric meningococcemia (Gordon and Romanowski 2005). Phase I 
clinical trials were recently completed on oral administration of the class II lantibiotic NVB302 for 
Clostridium difficile infections in humans (www.evaluatepharma.com, June, 2012). In 2012 two 
pharmaceutical companies (Oragenics and Intrexon) initiated a “lantibiotics program” in which they 
will focus on the development of lantibiotics. 
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3.1 Lactic acid bacteria and bacteriocins 
Lactic acid bacteria (LAB) are one of the most extensively studied and best characterized groups of 
bacteria and were even referred to as “the bugs of the new millennium” at the turn of the century 
(Konings et al. 2000).  They are Gram-positive, anaerobic bacteria with lactic acid as one of their main 
fermentation products and play an important part in the fermentation of milk products, vegetables, 
meat and wine because of their generally regarded as safe (GRAS) status approved by the United 
States Food and Drug Administration (FDA). LAB has the ability to produce bacteriocins, which are 
AMPs with activity against strains closely related to the producing species (Daw and Ikiner 1996).  
 
Since the discovery of bacteriocins in 1925 (Gratia 1925), they have been classified and reclassified 
numerous times (Daw and Ikiner 1996). Fredericq (1957) proposed a classification system based on 
the specificity of absorption and further sub classified them according to immunity (Fredericq 1957). 
Reeves implemented a system consisting of 16 classes of bacteriocins based on its producer species. 
Ten years later, Bradley (1967) designed a criterion for bacteriocin classification based on natural 
division, with two groups: low and high molecular weight forms. Klaenhammer (1993) classified 
bacteriocins into four classes based on structure, mechanism of action, genetics and biochemical 
properties. Cotter et al (2005) changed it to three groups: Lantibiotics (class I), heat-stable non-
lantibiotics (class II) and the bacteriolysins (class III).  
 
Rea et al. (2011) suggested sub classification of class 1 (a-c) bacteriocins, while class II consists of 
four subdivisions (a-d). Class 1a bacteriocins include, amongst others, nisin, subtilin, epidermin and 
Pep5, while the lantibiotics mersacidin, lacticin (3147 and 481), and nukacin ISK-1 belong to class Ib. 
Lantibiotics are bacteriocins of 19-38 amino acids and contain certain unusual amino acids and various 
circular structures (lanthionine rings). The latter aids this group of proteins in stability in terms of heat, 
pH, oxidation and proteolysis (Sahl et al. 1995; Bierbaum et al. 1996). Examples of class II 
bacteriocins include pediocin PA-1 and AcH (IIa), lactococcin G and Q (IIb), enterocin AS-48 and 
gassericin A (IIc) and lacticin Q and lactococcin A (IId) (Nishie et al. 2012). Class II bacteriocins are 
also heat stable. 
 
3.2 Nisin 
Nisin, a class Ia bacteriocin, is generally regarded as safe (GRAS) and due to its relatively low toxicity 
to humans (Fowler 1973), it has been used as a food preservative for decades (Van Heusden et al. 
2002). Since nisin will be used in this study, it will be discussed as a model bacteriocin. Nisin A 
(Mattick and Hirsch 1947), F (De Kwaadsteniet et al. 2008), U, U2 (Wirawan et al. 2006), Q (Zendo 
2003) and Z (Mulders et al. 1991) are small lantibiotics ribosomally synthesised by certain L. lactis 
species, with the exception of nisin U that is produced by Streptococcus uberis (Wirawan et al. 2006). 
These natural variants of nisin usually differ with only a few amino acids and have antimicrobial 
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activity against various Gram-positive species, including Staphylococcus, Listeria, Bacillus and 
Clostridium spp. (Breukink and De Kruijff 1999). Nisin have also shown activity against multidrug-
resistant strains such as MRSA and VRE (Kruszewska et al. 2004; Piper et al. 2010). Nisin consists 
of 34 amino acid molecules and contains five lanthionine or β-methyllanthionine rings (Sun et al. 
2009), as illustrated in Fig. 4. Unusual amino acids include dehdryalanine (Dha), dehydrobutyrine 
(Dhb), lanthionine (Ala-S-Ala) and 3-methyllanthionine (Abu-S-Ala).  
 
 
 
Figure 4 Comparison of structures of nisin A (illustrated as basis), Z, Q, F, U and U2 after post-
translational modification (adapted from Piper et al. 2010). 
 
3.2.1 Biosynthesis  
Nisin is produced on the ribosome of its producer cells. The initial precursor peptide consists of a 
leader peptide at its N-terminal and a pro-region (eventually to become the mature peptide) at its C-
terminal (Cotter et al. 2005; Willey and Van der Donk 2007; Bierbaum et al. 2009; Ross and Vederas 
2011). While inside the bacterial cell, the protein is kept inactive by the leader peptide, which is 
recognized by modification enzymes and subsequently cleaved off (Fig. 5). Class I lantibiotics are 
modified by the enzymes LanB and LanC – NisB and NisC in the case of nisin. NisB is responsible for 
the dehydration of serine (Ser) and threonine (Thr) residues to form Dha and Dhb, respectively, as 
illustrated in Fig. 6 (Patton and Van der Donk et al. 2005). NisC mediates cyclization of the 
dehydrated residues with intramolecular cysteine (Cys) to form lanthionine (Lan) or methyllanthionine 
(MeLan) rings. Subclass II lantibiotics on the other hand, rely on LanM for modification (both 
dehydration and cyclization).  
 
During the biosynthesis of nisin, the peptide interacts with various additional cellular compounds 
(Konings et al. 2000). After the precursor peptide has been modified, the leader peptide is cleaved of 
by a serine-type protease, LanP. The protease domain of the ATP-binding cassette protein, LanT, can 
also facilitate cleavage. The mature peptide is then secreted out of the cell by LanT. NisR 
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constitutively regulates transcription while the signal transducer histidine kinase, NisK, is involved in 
sensing nisin, allowing it to act as an extracellular regulator of its own biosynthesis (Kuipers et al. 
1995; Van Kraaij et al. 1999). 
 
 
Figure 5 Molecular components involved in the biosynthesis, regulation and immunity of nisin A 
(from Patton and Van der Donk 2005). 
 
NisRK acts as a two-component regulatory system. Similar autoregulation is also observed for 
epidermin (Peschel et al. 1993), subtilin (Kleerebezem et al. 1999; Kleerebezem 2004), mutacin II (Qi 
et al. 1999), lacticin 3147 (McAuliffe et al. 2001), SapB (Keijser et al. 2002; Nguyen et al. 2002; 
O’Connor and Nodwell 2005), mersacidin (Schmitz et al. 2006) and bovicin HJ50 (Ni et al. 2011).  
Nisin resistance genes nisI and NisFEG equip nisin-producing strains with immunity from its own 
bacteriocins (Engelke et al. 1994; Siegers and Entian 1995). While nisI acts as a specific immunity 
protein, NisFEG acts as an ABC transporter system (Draper et al. 2008). The expression of immunity 
genes have to be regulated very precisely to ensure activity the moment peptides are produced. 
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Figure 6 Posttranslational modification of amino acids of nisin A (from Mavaro et al. 2011). 
 
3.2.2 Mode of action  
Nisin exerts its antimicrobial activity in multiple unique ways. The main mechanism is binding to the 
cell wall precursor lipid II as illustrated in Fig. 7 (Breukink et al. 1999; Wiedeman et al. 2001; Wiley 
et al. 2007). Bound lipid II prevents cell wall biosynthesis in Gram-positive bacteria. The overall 
positive charge of nisin facilitates its mobilization to the negatively charged bacterial cell wall. The 
amide groups of the A and B lanthionine rings on the amino (N)-terminal of nisin binds to the 
pyrophosphate structures of the docking molecule lipid II, N-acetylmuramic acid (MurNAc) 
(Wiedemann et al. 2001; Hasper et al. 2004; Hsu et al. 2004;). A similar binding to lipid II without the 
formation of pores was observed in the lantibiotics subtilin, mutacin (Hasper et al. 2006), epidermin 
and gallidermin (Bonelli et al. 2006), while the antibiotics vancomycin and ramoplanin bind to the 
terminal D-Ala D-Ala residues (Patton and Van der Donk 2005; Wiley et al. 2007) and the class Ib 
lantibtiotic, mersacidin to the N-acetylglucosamine (GlcNAc) saccharide of lipid II. Transmembrane 
pores are formed after the bending of nisin at the flexible hinge region between the C and D rings and 
insertion of the carboxy (C)-terminal end into the phospholipid bilayer (Hsu et al. 2004; Van Heudsen 
et al. 2002). 
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Figure 7 The chemical structure of lipid II (A) and the binding mechanism of nisin to lipid II (B) 
(adapted from Patton and Van der Donk 2005). 
 
The pores generally consist of eight nisin and four lipid II molecules (Hasper et al. 2004) and have a 
diameter of 2-2.5 nm (Wiedemann et al. 2004). Pores cause an efflux of potassium ions, amino acids 
and ATP ions, which is detrimental to the bacterial cell (Van Heudsen 2002). The formation of pores 
can take place in one of three proposed models: the “wedge”, “barrel-stave” or “carpet” models (Sahl 
1991; Driessen et al. 1995; Moll et al. 1999; Hechard and Sahl 2002). The lantibiotic peptides use the 
wedge model (Moll et al. 1999).  
 
Nisin also has the ability to disrupt the functional localization of lipid II (Hasper et al. 2006). While 
lipid II is normally present at sites of emerging cell wall biosynthesis, treatment with nisin results in 
patches of dysfunctional lipid II across the bacterial membrane, away from the site of biosynthesis.  
 
Furthermore, nisin (and subtilin) has the ability to inhibit spore germination in some Bacillus and 
Clostridium species (Thomas et al. 2002; Montville et al. 2006; Gut et al. 2008). The mode of action 
seems to be connected to the residue in position 5 of the lantibiotic. Replacement of dehydroalanine 
normally present at position 5, showed enhanced inhibition of spore outgrowth (Rink et al. 2007). 
 
Nisin and Pep5 were also shown to induce autolysis in Staphylococcal strains. In this case, the mode 
of action involves the binding of nisin to lipoteichoic and teichoic acids of the cell and displacing and 
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activating N-acetyl-alanine aminidase and N-acetylglucosaminidase supposed to interact with 
lipoteichoic and teichoic acids (Bierbaum and Sahl 1985). 
 
3.2.3 Resistance 
The combination of the mode of action of nisin (pore formation, inhibition of cell wall biosynthesis, 
cell autolysis and the inhibition of spore outgrowth) gives it a unique advantage over other 
antibacterial compounds. Although these features decrease bacterial resistance development to nisin, it 
is not impossible. 
 
Resistance to nisin was reported as early as the 1960’s, with the proteolytic enzymes collectively 
termed nisinase (Jarvis 1967). The enzyme was later identified as a dehydroalanine (Dha) reductase, 
with the ability to reduce carboxyl Dha to Ala to inactivate nisin (Jarvis and Farr 1971). Resistant 
strains of Streptococcus spp. (Alifax and Chevalier 1962; Galesloot 1956; Lipinska and Strzalkowska 
1959), B. subtilus, B. licheniformis, B. cereus (Jarvis 1967), S. aureus (Carlson and Bauer 1957; Jones 
1974), L. monocytogenes (Harris et al. 1991; Ming and Daeschel 1993; Mazzotta and Montville 1997) and 
C. botulinum (Mazzotta et al. 1997) developed.  Particular concern was raised by a study where nisin-
resistant Streptococcus bovis mutants showed 1000 times greater resistance to ampicillin, in 
comparison to their nisin-susceptable predecessors (Mantovani and Russel 2001). This phenomenon is 
termed cross-resistance. Another case of acquired multidrug-resistance was observed when Salmonella 
enterica was exposed to the AMP, microcin (Carlson et al. 2001).  
 
Although much less than for conventional antibiotics, a number of genes have been assigned to 
bacterial resistance to AMPs and bacteriocins. Resistance can be acquired in response to repeated 
exposure to increasing concentrations of the peptide. In this case, the microorganism alters expression 
of its genes involved in the general composition of the cytoplasmic membrane biosynthesis - from 
there the term physiological adaption (Peschel et al. 1999; Thedieck et al. 2006; Sun et al. 2009). ABC 
transporters (Kramer et al. 2006; Draper et al. 2008; Hansen et al.; 2009) or regulators and two-
component signal transductions systems (Cotter et al. 1999; Kallipolitis et al. 2003; Mascher et al. 
2004; Gravesen et al. 2004; Guinane 2006) are other forms of resistance. Genes encoding ABC 
transporters involved in nisin resistance include ysaBC in L. lactis (Kramer et al. 2006), yvcRS in B. 
subtillis (Hansen et al. 2009), sp0913 and sp0912 in S. pneumonia (Sass et al. 2008). The transporter 
encoded by vraDE provides S. aureus with resistance to the class II lantibiotic mersacidin. Kramer et 
al. (2006) suggested a putative nisin resistance pathway in L. lactis with four mechanisms of action: 
(A) - thickening of the bacterial wall to prevent nisin from binding to lipid II (pbp2A), becoming 
packed more densely (galE and pbp2A) or less negatively charged (dltD); (B)  expressing genes 
encoded by the arc operon to increase pH outside of the cell wall and possibly degrade nisin; (C) 
increasing fluidity of the membrane by decreasing expression genes of the fab operon responsible for 
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the saturation of membrane phospholipid fatty acids, which possibly prevents nisin from inserting into 
the membrane and (D) ABC transporters pumping nisin out of the membrane and preventing binding 
to lipid II.  
 
Most research on nisin resistance has been done on L. monocytogenes and the genes involved are 
listed in Table 3. The nisin resistance protein (NSR) was discovered by Froseth and McKay (1991), 
with additional studies revealing its ability to cleave nisin between MeLan (position 28) and Ser 
(position 29, Sun et al. 2009). An important factor in the bacterial stress response is the alternative 
sigma factor SigB, which was found to reduce the sensitivity of L. monocytogenes to nisin and lacticin 
3147 (Begley et al. 2006). The signal-transduction system LisRK and the VirRS system, which 
controls the expression of dltA and mrpF, also plays a role together with the pbp, anrB, telA, and gad 
genes. VirRS controls the expression of the dlt-operon, involved in alanylation of the lipoteichoic 
acids in the cell envelope, and mprF, conferring resistance to cationic antimicrobial peptides (CAMPs) 
(Abachin et al. 2002; Mandin et al. 2005; Thedieck et al. 2006). The ability of L. monocytogenes to 
sense antimicrobial agents, ethanol and lysozyme are conferred by CesRK. CesRK also regulates 
orf2420, responsible for virulence in mice. LisRK aids the pathogen to sense and enhance virulence 
against nisin and other harmful molecules such as ethanol, acid and hydrogen peroxide stress 
(Kallipolitis et al. 2003). 
 
Table 3 Genes rendering resistance of Listeria monocytogenes to nisin 
Gene Function Reference 
nsr Nisin resistance protein Froseth and McKay 1991; 
Sun et al. 2009 
pbp Penicillin-binding protein Gravesen et al. 2001, 2004 
lisRK LisRK signal transduction system Cotter et al. 1999, 2002 
dltA & mprF Two-component regulatory system VirRS Mandin et al. 2005 
SigB Sigma factor B Begley et al 2006 
anrB Permease component of ABC transporter Collins et al. 2010a 
telA Telurite resistance  Collins et al. 2010b 
gad Glutamate decarboxylase Begley et al. 2010 
lmo1021 & lmo1022 LiaSR two-component signal transduction system Collins et al. 2012 
CesR, CesK & , orf2420 CesRK two-component signal transduction system Kallipolitis et al. 2003 
 
3.2.3 Applications 
Nisin has been applied in the food industry for more than 50 years. Due to its FDA-approved status 
and specific mode of action, it reduces the chances of the development of bacterial resistance. Due to 
its activity against plaque and gingivitis-causing bacteria, nisin has been incorporated in mouthwashes 
(van Kraaij et al. 1999). A number of studies applied nisin in the treatment of mastitis, a bacterial 
infection of the mammary glands. Mastitis is known to cause huge economic losses in the dairy 
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industry (Soltys and Quinn 1999; Sordelli et al. 2000; Twomey et al. 2000; Riffon et al. 2001; Bradley 
2002). Intramammary infusions of nisin effectively treated streptococcal and staphylococcal mastitis-
related infections (Taylor et al. 1949). In another study in vivo, Broadbent et al. (1989) showed that 
nisin inhibited the growth of several Gram-positive, mastitis-causing pathogens. Sears et al. (1992) 
acquired 66% inhibition of S. aureus, 95% of Streptococcus agalactiae, and 100% for Streptococcus 
uberis after combining nisin A and lysostaphin in intramammary infusions. Nisin A was also applied 
in teat wipes (Broadbent et al. 1989; Ross et al. 1999; Cotter et al. 2005).  
 
Contaminated biomedical implant devices are the cause of serious surgical (Campoccia et al. 2005). 
Nisin, adsorbed to silanized surfaces, successfully prevented the growth of L. monocytogenes (Bower 
et al. 1995). Intravenous catheters and tracheotomy tubes coated with nisin were implanted in sheep 
and ponies, respectively (Bower et al. 2002). The endotracheal tubes prevented colonization of S. 
aureus, S. epidermidis, and S. faecalis. The authors, however, concluded that the antimicrobial activity 
of nisin may be short lived in vivo, as the peptide controlled bacterial infection for only 5 h in sheep. 
However, the tracheotomy tubes retained activity for seven days (Bower et al. 2002). 
 
Nisin was also applied in the treatment of respiratory tract infections. Nisin inhibited S. pneumonia 
associated with otitis media in vivo (Goldstein et al. 1998). Additionally, Nisin F inhibited S. aureus in 
the nasal cavities of immunosuppressed rats (De Kwaadsteniet et al. 2009). When applied together 
with polymyxin E and clarithromycin, nisin inhibited the growth of P. aeruginosa (Giacometti et al. 
1999). A number of studies found nisin effective against diarrhoea-causing Clostridium species i.e. C. 
botulinum (Delves-Broughton et al. 1996) C. tyrobutyricum (De Carvalho et al. 2007) and C. difficile 
(Bartoloni et al. 2004). Another possible application is the treatment of peptic ulcers, since nisin 
successfully inhibited Helicobacter pylori in vitro (Delves-Broughton et al. 1996; Kim et al. 2003). 
Commercially produced nisin is in phase I clinical trials for treatment of gastric conditions and oral 
mucositis, while both nisin A and Z are in preclinical trials against vancomycin-resistant enterococci 
(VRE). Lastly, nisin has excellent spermicidal activity. It was successfully applied as a contraceptive 
in rats, with restored fertility after trials (Aranha et al. 2004). This finding could lead to an 
improvement on current contraceptive products, since many of them contain Nonoxynol-9 (N-9), a 
compound harmful to epithelium cells. 
 
3.3 Limitations of bacteriocins and possible solutions 
As previously mentioned, most clinical trials involving AMPs are limited to topical applications and 
not systemic application. In addition, resistance to almost every known antimicrobial compound has 
been reported and for the lucky few, it is probably only a matter of time. Since AMPs mostly interact 
with bacterial membranes to exert its activity, resistance is mostly acquired through alterations in the 
bacterial membrane (Ming and Daeschel 1993; Mazzotta et al. 1997; Crandall and Montville 1998).  
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Another major disadvantage of AMPs is their limited in vivo stability due to proteolytic degradation 
inside the intestines, tissues serum and kidneys of the host (Joerger 2003; McGregor 2008). The 
terminal parts of the peptides are prone to enzymatic degradation by aminopeptidases and 
carboxypeptidases, whilst various endopeptidases can target specific cleaving sites within the peptide 
(Rink et al. 2010). Trypsin will cleave cationic amino acids like lysine and arginine (Svenson et al. 
2008; Park et al. 2009), while chymotrypsin cleaves phenylalanine, tryptophan and tyrosine, and 
elastase cleaves  alanine, glycine, and valine (Gray and Cooper 1971). AMPs like defensins (Kagan et 
al. 1994) and bactencin (Rademacher et al. 1993) produce toxins and are prime targets for in vivo 
proteolytic inactivation as a mechanism to decrease the concentration and potency of the bacteriocin. 
Probably due to this fact, successful application of nisin is mostly limited to topical applications.  
 
Since the ring-formations in lantibiotics enhance their stability, the introduction of D-amino acids 
(Besalle et al. 1990; Hong et al. 1999) and cyclization (Li and Roller 2002) are possible options to 
enhance the stability of bacteriocins. Rink et al (2010) combined the two techniques to create peptides 
with enhanced ex vivo stability. Other techniques includes conjugation of fatty acids (Avrahami and 
Shai 2002), substitution by peptoids (Chongsiriwatana et al. 2008; Wang et al. 2009) and 
incorporation of beta-peptides (Porter et al. 2002), fluorinated amino acids (Meng and Kumar 2007) 
and acylation (Radzishevsky et al. 2007). Peptide engineering on nisin include incorporation of its 
unique biosynthethic genes onto unrelated peptides with improved in vitro and in vivo activity and 
stability (Kuipers et al. 2006; Kluskens et al. 2009; Kuipers et al. 2009; Majchrzykiewicz et al. 2010; 
Moll et al. 2010). Recently, Field and co-workers created nisin S29 derivatives with antibacterial 
activity against Gram-positive as well as Gram-negative pathogens (Field et al. 2012). 
 
Another route to overcome peptide degradation is the development of drug delivery systems. One such 
example is to protect the protein inside a polymer complex that will systematically release the active 
protein as the polymer matrix dissolves. This application was successfully implemented in food 
preservation, but very few systems are available for medical application (Balasubramanian et al. 
2009). When encapsulated in poly (L-lactide) (PLA) nanoparticles, released nisin inhibited the in vitro 
growth of Lactobacillus delbrueckeii subsp. bulgaricus (Salmaso et al. 2004). In another study, the 
bacteriocin plantaricin 423, released from electrospun nanofibers consisting of polyethylene oxide 
(PEO) successfully inhibited growth of Lactobacillus sakei and Enterococcus faecium (Heunis et al. 
2010). Similar fibers containing nisaplin (nisin A) successfully treated S. aureus-infected burn wounds 
in mice when applied as an antibacterial dressing (Heunis 2012). Nisin F incorporated in bone cement 
(similar to implants used for hip replacements) successfully prevented S. aureus growth when inserted 
into infected subcutaneous pockets as a prophylactic treatment in mice (Van Staden et al. 2012). 
 
Due to the small size of AMPs, they are easily adsorbed by the kidneys during circulation through the 
host (Jeong et al. 2010). Strategies to increase stability in sera include the lengthening of peptides 
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through the attachment of polyethylene glycol (PEG), referred to as PEGylation (Veronese and Mero 
2008; Pasut and Veronese 2009; Jevsevar 2010). Although also decreasing cytotoxicity of peptides, 
PEGylation unfortunately has a negative effect on in vitro activity (Imura 2007a, b). This obstacle was 
overcome in a study using shorter PEGylation (Zhang et al. 2008). 
 
The large-scale production of active, purified bacteriocins is very expensive (Joerger 2003). To cross 
this financial obstacle, Van t’Hof et al. (2001) suggested transgenic plants as an option. In the food 
industry, nisin can be applied in combination with traditional food preservation mechanisms such as 
acidification and increased salt concentration (Harris et al. 1991; Mazzotta and Montville 1997), 
hydrostatic pressure, heat treatment, refrigeration, (Roberts and Hoover 1996; De Martinis et al.1997) 
or additives (Taylor et al. 1985). The synergistic effect increases the antimicrobial effect of nisin 
whilst decreasing the formation of nisin-resistant strains. In a study on nisin-resistant strains, Mazzotta 
et al. (2000) showed that the combination of nisin and food preservatives did not result in cross-
resistance and had no effect on the susceptibility of bacterial strains to preservatives. 
 
4. Bioluminescent imaging  
Biomedical research has become very reliant on imaging techniques in recent years. Instrumentation 
for imaging small animals include x-ray computed tomography (CT), magnetic resonance imaging 
(MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET, or microPET), 
single photon emission computed tomography (SPECT, or microSPECT), ultrasonography, and 
optical imaging, including fluorescence and bioluminescence (Zinn 2008). Optical imaging is less 
expensive and time consuming than other techniques mentioned. Bioluminescence (or 
chemiluminescence) imaging (BLI) is based on the detection of imaging contrast formed by light 
emission from a reporter protein called luciferase. Luciferase catalyzes the conversion of D-luciferin 
to oxyluciferin. BLI has been used to effectively monitor transgene expression, tumor growth and 
metastasis, development of infection, transplantations, toxicology, viral infections and gene therapy 
(Benaro et al. 1997; Contag et al. 1997; Edinger et al. 1999; Koransky et al. 2001). Organisms, cells or 
genes are genetically modified to express the luciferase enzyme in the presence of oxygen, magnesium 
(Mg), adenosine triphosphate (ATP) and the substrate D-luciferin if needed. D-luciferin can also be 
administered to animals by intravenous (i.v.) or intraperitoneal (i.p.) injection, osmotic pumps (Gross 
et al. 2007) or in drinking water (Gross et al. 2007; Hiler et al. 2006).  
 
Various luciferases are used in optical imaging, but the most popular is luciferase from the North 
American firefly (Photinus pyralis; FLuc). Other useful luciferases have been cloned from the sea 
pansy (Rinilla; RLuc), jellyfish (Aequorea), corals (Tenilla), the click beetle (Pyrophorus 
plagiophtalamus) and various bacteria (Vibrio fischeri, V. harveyi) (Hastings 1996). Luciferases vary 
in substrate specificity, wavelength of light emission and optimal parameters (Zhao et al. 2005), but 
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more than one luciferase can be imaged simultaneously. Bacterial species can also bioluminesce, but 
in this case employ long-chain aldehydes and flavin mononucleotides in combination with 
heterodimeric luciferases. Luciferases and all proteins required for substrate biosynthesis are encoded 
by a single lux operon (Contag et al. 1995). The luxCDABE operon originally suitable for Gram-
negative organisms only, was genetically modified to luxABCDE for use in Gram-positive organisms. 
The fatty acid reductase complex involved in synthesis of the fatty aldehyde substrate for the 
bioluminescence reaction is encoded by luxCDE. The luxAB-genes encode the luciferase enzyme.  
 
A few factors determine the sensitivity of detection: the level of luciferase expression, the depth of the 
labelled cells inside the animal, and the sensitivity of the detection system (Wilson and Hastings 
1998). BLI can detect bioluminescence and fluorescence with a specialized charged coupled device 
(CCD) camera. The camera has the ability to convert emitted photons into electrons. Images are 
generated by encoding the intensity of the photons to electrical charge patterns. Background noise is 
eliminated by cooling the camera down to -90˚C and taking images in a light-tight box. The system is 
controlled by a computer where the operator can also acquire and analyse images. Heat (usually 37˚C) 
is also provided to maintain body temperature. Image acquisition can take from as long as 1 second to 
10 minutes and the imaging software ensure that no pixels are saturated during imaging.  
 
A colour scale represents the light intensities of each image and allows the researcher to measure and 
compare the rate of light emitted from different areas (regions of interest) on a specific image. The 
colour scales of two or more images can be standardized to the same minimum (violet) and maximum 
(red) values to allow comparison among images. Such a bioluminescent image is overlaid on a black 
and white image of the animal. The software can be manipulated to measure light (relative or absolute) 
emitted from certain region(s) of interest (ROI) on an image or numerous images. Light emission can 
be relatively quantified as total flux (photons/second), the radiance in each pixel summed or integrated 
over the ROI area (cm2x4Π) or absolute as average radiance (photons/second/cm2/steridian), photons 
per second of light that radiate from the mouse in a unit area (1 cm2) and unit angle (1 steridian). 
 
BLI has various advantages over normal animal models. The spatial and temporal course of diseases 
can be detected from the same animal without killing it. The animal serves as its own negative control, 
which further decreases the amount of experimental animals and biological variation. These animal 
models can lead to more trustworthy and accurate predictions on how humans will react to involved 
agents (Sadikot and Blackwell 2005). BLI is also relatively inexpensive and accessable to any 
scientist, as specialised operators are not required (Luker and Luker 2010). Also, BLI has a signal-to-
noise ratio with only little background light from chlorophyll pigments present in ingested food. The 
technique is also less time-consuming, allowing a researcher to monitor more animals in a specific 
subgroup. Unexpected sites of infection can also be detected by BLI, which would otherwise have 
been overseen with the use of conventional techniques where only specific body parts or organs of 
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animals are examined post mortem. Recently advanced systems have been developed to allow 
researchers to obtain 3-dimentional images using x-ray technologies (Cronin et al. 2012). 
 
Like every other technique, BLI also has its own limitations. The most important one is the attenuation 
of the signal through absorption and scattering of light by hemoglobin, melanin and other pigmented 
particles present in mammalian tissues (Contag et al. 1995). It is thus important to consider the latter 
when monitoring superficial and deep infections simultaneously. Also, two-dimensional images 
obtained through BLI, complicate specific allocation of infection inside the animal. Another drawback 
of BLI is the requirement of oxygen and ATP, which limits in vivo applications to aerobic conditions 
(for instance, not intragastric). Foucault et al. (2010) engineered an E. coli strain which enabled 
bioluminescent studies in the GIT of mice. 
 
The field of optical imaging and its use in animal studies are widely studied and continually evolving 
(Leevy et al. 2007; Luker et al. 2008; Dothager et al. 2009; Luker and Luker 2010; Prescher et al. 
2010; Andreu et al. 2011; Close et al. 2011; Waidmann et al. 2011). 
 
5. In vivo infection models 
Mice are ideal animals to study human infectious diseases, due to the high similarity in immune 
systems (Flajnik 2002). BLI has been included in various in vivo studies monitoring gene expression, 
protein stability, bioactive small molecules, tracking cells and therapeutic delivery (Prescher and 
Contag 2010). Studies of particular interest (systemic administration and nisin F) will be discussed 
(Table 4). Firstly, the bacteriocin mutacin B-Ny266 was intraperitoneally (i.p.) injected into mice 
infected with 3.1 × 107cfu S. aureus Smith immediately prior to treatment (Mota-Meira et al. 2005). 
The bacteriocin protected animals from mortality, as seen in the control groups. Secondly, 
microbisporicin effectively cured septicemic mice i.p. infected with 1 × 106 cfu of S. aureus Smith 819 
ATCC 19636 (Castiglione et al. 2008). Thirdly, Nisin F showed no adverse histological effects or 
weight gain when applied as treatment to 4 × 105 cfu of S. aureus K administered to the nostrils of 
immunocompromised animals (De Kwaadsteniet et al. 2009). In a related study, C57BL/6 mice were 
subcutaneously (s.c.) infected with 4 × 106 cfu of the bioluminescent S. aureus strain xen 36 (De 
Kwaadsteniet et al. 2010). Infections were treated with 256 Au of nisin F, also s.c. administered. No 
significant differences in bioluminescence could be recorded. Recently, Piper et al. (2012) showed that 
lacticin 3147 prevented the systemic spread of BALB/C mice i.p. infected with 1 x 106 cfu S. aureus 
Xen29, a bioluminescent strain. 
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Table 4 In vivo bacterial infection models 
Aim of study Reference 
Investigating the effectiveness of antibiotics in treating infections in the thigh muscles of mice Francis et al. 2000 
Monitoring the effectiveness of antibiotics on biofilms on catheters planted in mice Kadurugamuwa et al. 2003, 2004, 2005;  
Yu et al. 2005  
Monitoring staphylococcal foreign-body and deep-thigh-wound infections in mice Kuklin et al. 2003 
Treatment of MRSA infections with the lanbtibiotic mersacidin in mouse rhinitis model Kruszewska et al 2004 
Investigating the effectiveness of antibiotics in a rat endocarditis model Xiong et al. 2005 
In vivo activity of mutacin B-Ny266 with i.p. injection in mice     Mota-Meira et al. 2005 
Antibiotic treatment to a Pseudomonas aeruginosa urinary bladder infection  Kadurugamuwa et al. 2005 
Open wound Escherichia coli infections in rats Jawhara and Mordon 2006 
Investigating the antimicrobial activity of daptomycin against S. aureus peritonitis infections  Mortin et al. 2007 
Organ-specific bioluminescent monitoring of Listeria monocytogenes infection in mice after 
i.v. injection 
Riedel et al. 2007 
Fetoplacental listeriosis  and the pathogen’s ability to cross the placental barrier in mice  Disson et al. 2008 
Monitoring implant-associated osteomyelitis infections  Li et al. 2008 
Monitoring the spread of a staphylococcal infection on implanted biomaterial Engelsman et al. 2008 
Treatment of subcutaneous S. aureus infections in mice with nisin F De Kwaadsteniet et al. 2009 
Respiratory tract S. aureus infection in rats treated with nisin F De Kwaadsteniet et al. 2010 
Prophylactic treatment of subcutaneous S. aureus infections in mice with nisin F incorporated 
into bone cement 
Van Staden et al. 2012 
Treatment of S. aureus infected burn wounds with nisin A-nanofiber dressings Heunis 2012 
Monitoring systemic spread of S. aureus treated with the lantibiotic lacticin 3147 and the 
antibiotic vancomycin in a mouse peritonitis model  
Piper et al. 2012 
 
6. Drug development  
The development of a drug for commercial use can take up to 13 years and a few critical aspects needs 
to be taken into consideration. In the case of antimicrobials, the drug needs to show in vitro 
antimicrobial activity. Additional in vitro and ex vivo tests can lead researchers to conclusions as to 
how the drug might react in an in vivo situation, but due to the extreme complexity of the situation 
once inside a living host, it brings about its own set of uncertainties.  
 
Any compound entering the body exerts a certain immunomodulatory effect, either 
immunostimulatory or immunosuppressive. The innate immune system acts as the first line of defence 
and recognizes and responds to the first signs of infection (Hoffmann et al. 1999). In addition to 
pathogens formerly dealt with, the innate immune system can also initiate responses to new pathogens 
due to the recognition of highly conserved motifs present in pathogens, pathogen-associated molecular 
patterns (PAMPs, Bannerman et al. 2004). PAMPs include lipopolysaccharide (LPS), peptidoglycan 
(PGN) and lipoteichoic acid (LTA), which form part of the bacterial cell wall. One of the primary 
functions of the innate immune system is the upregulation of cytokine production (Dinarello 1996; Koj 
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1996; Suffredini et al. 1999). Cytokines, in turn, act as messengers to various types of immunological 
cells to facilitate their movement to the site of infection. 
 
Similar to pathogens causing infection or inflammation, treatments foreign to the host can also cause 
an antigenic effect. The treatment might, for instance, be toxic to eukaryotic cells or seen as a threat 
and be removed from the system or degraded. Thus it is important to assess the immunomodulatory 
effect any drug might have on a host and take it in consideration during dosage determination. 
Information about the immunomodulatory properties of bacteriocins is limited. Bedge et al. (2011) 
found a commercially purified mixture of nisin A and Z to be toxic to human lymphochytes and 
neutrophils from whole blood. After administration of Nisaplin® (a commercial form of nisin A) to 
mice for 30 and 75 days, an increase in CD4 and CD8 T-lymphocytes and a decrease in B-
lymphocytes were observed (De Pablo et al. 1999). After 100 days of administration, the effects were, 
however, normalised again. The authors also found enhanced phagocytic activity of peritoneal cells 
after long-term administration of nisaplin. In another study, nisin showed immunostimulatory effects 
on head kidney macrophages in fish (Villamil et al. 2003). When administered to rats as a vaginal 
microbicide, RP-HPLC purified nisin proved to be non-toxic to host cells (Gupta et al. 2008). Nisin 
(Suárez et al. 1996), pediocin (Martínez et al. 1997) and peptide AS-48 (Maqueda et al. 1993) also 
showed an immunogenic effect in antibody studies. 
 
In vivo results in the presence of plasma and other complexities often differ greatly from in vitro 
results (Bracci et al. 2003; Pini et al. 2005). Because AMPs (including some conventional antibiotics) 
are foreign to the host, the peptides often get targeted by the immune system. Protein binding (PB) is a 
phenomenon which can be studied in many ways and should be included in the preclinical testing of 
any new drug. Drugs with protein binding higher than 70% need to be assessed very accurately in 
terms of PB and findings should be taken into consideration in dosage design (Craig and Kunin 1976). 
Firstly, since only its unbound fraction is free to diffuse to the site of infection (Ogren and Cars 1985; 
Cars 1990; Kovar et al. 1997; Scaglione et al. 1998) and secondly because suboptimal dosages could 
lead to antimicrobial resistance (Schmidt et al. 2007). Generally, an increase of MIC was observed in 
serum for small molecule antibiotics (Chambers et al. 1984; Jones and Barry 1987; Lam et al. 1988) 
and peptide antibiotics such as LY333328 (Zhanel et al. 1998), daptomycin (Lee et al. 1991), and 
vancomycin (Dykhuizen et al. 1995). Only one lantibiotic, MU1140 has been tested in serum 
(Ghobrial et al. 2010), where the authors found contradicting results, where the MIC of the lantibiotic 
against S. aureus decreased in the presence of 50% serum. However, when tested against S. 
pneumoniae, the MIC increased in increasing serum concentrations. When analyzing PB, it is 
important to use a purified form of the drug in order to determine dosages accurately. 
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Currently only a few antibiotics are available to treat infections caused by Gram-positive 
microorganisms (Upton et al. 2012). Big pharmaceutical companies have not made significant 
investments over the last few decades due to the time and financial constraints related to the drug 
development process. The global increase in antibiotic resistance and untreatable infections are not 
only widely discussed, but also leads to downstream complications. With further increased resistance, 
complications in surgical procedures and restricted cancer chemotherapy could be at the order of the 
day. To prevent this from happening, a combination of actions will need to be taken, including 
responsible use of antibiotics by both professional and public members, as well as the development of 
novel drugs. 
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Abstract Mice intragastrically infected with Listeria monocytogenes EGDe and Staphylococcus 
aureus Xen 36 showed no visible signs of infection over 48 h.  However, high numbers (6.2 x 105 
cfu/mg feces) of S. aureus Xen 36 were detected 4 h, and 3.3 x 105 cfu/mg feces of L. monocytogenes 
EGDe 8 h, after administration.  Mice intraperitoneally infected with S. aureus Xen 36 (1 x 107 cfu) 
developed infection immediately after administration and for at least the following 48 h.  Injection 
with higher cell numbers of S. aureus Xen 36 (2 x 108 cfu) resulted in more intense bioluminescence 
(infection) of the peritoneal cavity.  Injection of S. aureus Xen 36 in the tail and penile veins resulted 
in localized tissue infection for the first 120 h.  Injection of S. aureus Xen 36 into the thigh produced a 
faint bioluminescent signal for 15 min.  Nisin F injected into the peritoneal cavity at the same area of 
infection led to an immediate statistically significant decrease in infection (from 2 x 106 p/s/cm2/sr to 3 
x 105 p/s/cm2/sr), which was maintained for 2 h.  Similar results were recorded when nisin F was 
injected subcutaneously. Intraperitoneal administration is an optimal administration route for bacterial 
infection and treatment with antimicrobial peptides. 
 
Keywords  Bioluminescence imaging, Infection Model, Staphylococcus aureus 
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Introduction 
Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) are the most prevalent organisms 
in skin infections and are considered a serious problem, especially in hospitals [10, 21].  MRSA was 
first reported in the 1960’s after the introduction of methicillin in the treatment of S. aureus infections 
[11, 12].  Since then, new enteropathogenic strains of MRSA, capable of rapid molecular changes, 
have been described [14, 16].  Symptoms vary from minor skin and soft tissue infections (SSTIs) to 
more serious diseases such as bacteraemia, toxic shock syndrome, endocarditis and pneumonia [13]. 
Staphylococcus aureus infections are treated with oxacillin, nafcillin, quinopristin-
dalfopristin, rifampicin, ciprofloxacillin, teichoplanin, cefazolin, mupirocin and cephalothin A, but 
with limited success [9, 13].  In many cases, vancomycin is used as last resort, but also with limited 
success [20].  De Kwaadsteniet et al. [7] and Brand et al. [2] reported on nisin F, a class Ia lantibiotic 
[6], with in vivo antimicrobial activity against S. aureus in animal models.  In these studies, 
bioluminescent imaging (BLI) was used to record changes in levels of S. aureus infection in vivo. 
In this study, in vivo migration of S. aureus Xen 36, a strain originally isolated from a 
bacteremia patient and deposited as S. aureus ATCC 49525, was studied in different body parts of 
mice. Strain Xen 36 is bioluminescent in that it contains a plasmid with the luxABCDE operon of 
Photorhabdus luminescence encoding the luciferase enzymes and substrates required for 
bioluminescence [8].  Infections were treated with nisin F. 
 
Materials and Methods 
Approval for in vivo experiments was obtained from the Ethics Committee of the University of 
Stellenbosch (ethics reference number: 2008B02003A2).  Male C57BL/6 mice weighing between 20 
and 30 g were used in all experiments.  The animals were housed under controlled environmental 
conditions and fed a standard rodent diet. 
 
Bacterial Strains 
Bioluminescent bacteria with the luxABCDE operon of Photorhabdus luminescence were purchased 
from BiowareTM Microorganisms (Caliper Life Sciences, Hopkinton, MA, USA). The strains were 
cultured at 37°C in specific growth media supplemented with antibiotics (Table 1), as prescribed by 
the supplier.  Cells were grown to exponential phase, harvested and washed twice with sterile saline 
(15300g, 10 min, 4°C).  A dilution series was prepared and the optical density of each cell suspension 
recorded at A600nm.  Listeria monocytogenes EGDe, containing the pMK4 luxABCDE plasmid [8], was 
cultured at 37°C in Brain Heart Infusion (BHI), supplemented with 75 µg/ml chloramphenicol.  
Lactococcus lactis subsp. lactis F10, the producer of nisin F, was cultured at 30°C in De Man Rogosa 
Sharpe (MRS) broth (Biolab, Biolab Diagnostics, Midrand, South Africa). 
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Table 1 Bioluminescent strains used in this study 
Strain Origin Growth medium 
Pseudomonas aeruginosa Xen 5 Septicemia isolate, 
ATCC19660 
 
LB, 60 µg/ml tetracyclin 
Escherichia coli Xen 14 Clinical isolate, 
WS2572  
 
LB, 30 µg/ml kanamycin 
Salmonella typhimurium Xen 26 Clinical isolate, 
SL1344 
 
LB, 30 µg/ml kanamycin 
Staphylococcus aureus Xen 29 Pleural fluid isolate 
NCTC8532 
 
BHI, 200 µg/ml kanamycin 
Staphylococcus aureus Xen 30 Clinical MRSA 
isolate, I6 
 
BHI, 200 µg/ml kanamycin 
Staphylococcus aureus Xen 31 Clinical MRSA 
isolate,  
ATCC 33591 
 
BHI, 200 µg/ml kanamycin 
Staphylococcus aureus Xen 36 Clinical isolate from 
bacteremia patient, 
ATCC49252 
 
BHI, 200 µg/ml kanamycin 
Klebsiella pneumonia Xen 39 Clinical isolate, 93A 
5370 
LB, 30 µg/ml kanamycin 
Listeria monocytogenes EGDe 
 
BHI, 75 µg/ml chloramphenicol 
LB= Luria Bertani (Biolab)  
BHI= Brain-Heart Infusion (Biolab)  
 
Nisin F Preparation and Activity Tests 
Lactococcus lactis subsp. lactis F10 was cultured anaerobic for 18 h at 37°C in MRS broth.  The cells 
were harvested (11300g, 20 min, 4°C) and nisin F was precipitated from the cell-free supernatant with 
80% ammonium sulphate according to Sambrook et al. [18].  The precipitate was harvested (22100g, 
60 min, 4°C) and dialysed against sterile distilled water, using a 1000 molecular weight cut-off 
membrane (Spectra/Por® Dialysis Membrane, Spectrum Laboratories, Inc. Rancho Dominguez, CA, 
USA). The desalted preparation was concentrated by freeze-drying and stored in cryotubes at -80°C. 
Antimicrobial activity of nisin F against the target strains listed in Table 1 was determined by 
using the agar-spot test method [22].  Plates were seeded with 18 h-old cultures diluted as follows:  
Separate test tubes with 10 ml sterile saline were each inoculated with 100 μl of culture.  From this 
suspension, 1 ml was used to inoculate 10 ml sterile soft agar (1%, w/v), supplemented with 
antibiotics as listed in Table 1.  Freeze-dried nisin F was suspended in 500 µl sterile water to a final 
concentration of approximately 54 mg/ml, of which 10 μl (±32 Au) was used to spot onto each of the 
seeded agar plates.  Formation of inhibition zones was recorded after 18 h of incubation at 37°C. 
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Intragastric Injection 
Eighteen mice were anaesthetized with 2% (v/v) isoflurane (Isofor, Safe Saline Pharmaceuticals, 
Florida, South Africa).  Six mice in group 1 were intragastrically infected with 200 µl (1 x 107 cfu) S. 
aureus Xen 36 and six mice in group 2 with 200 µl (3 x 107 cfu) L. monocytogenes EGDe to represent 
an acute form of infection.  Six mice in group 3 received 200 µl sterile saline administered with a 
straight oral dosing cannula (20 g x 76 mm, Harvard Apparatus Ltd., Edinbridge, UK). 
Fecal samples were collected before infection and 2, 4, 6, 8, 24 and 48 h after infection.  
Samples were then weighed, dissolved in sterile distilled water and plated onto BHI Agar (Biolab), 
supplemented with 200 mg/ml kanamycin, to detect S. aureus Xen 36 and onto BHI Agar, 
supplemented with 75 mg/ml chloramphenicol, to detect L. monocytogenes EGDe.  Samples collected 
from mice in group 3 were plated onto BHI Agar supplemented with kanamycin and chloramphenicol, 
respectively.  Plates were incubated at 37°C for 18 h and then scanned for bioluminescence using the 
IVIS® 100 In Vivo Imaging System (Caliper Life Sciences).  Photons emitted at 490 nm were 
quantified with Living Image® software, version 3.0 (Caliper Life Sciences) by measuring the average 
radiance in photons/ cm2/ second/ steridian (p/s/cm2/sr) from automatically created regions of interest 
(ROIs). 
In a separate experiment, one mouse infected with L. monocytogenes EGDe for three 
consecutive days was imaged in the IVIS® 100 Imaging System for 14 consecutive days.  On the last 
day, the animal was intraperitonealy administered with 200 mg/kg of pentobarbitone sodium 
(Euthapent, Kyron Laboratories (Pty) Ltd., Benrose, South Africa) and killed by exsangination 
(cardiac puncture).  Sections of the duodenum, ileum and jejunum were each placed in 1 ml sterile 
distilled water, crushed with a sterile spatula and 100 µl plated out onto BHI Agar, supplemented with 
200 mg/ml kanamycin.  Plates were incubated overnight at 37°C and imaged for the presence of 
bioluminescent colonies as described before. 
 
Intraperitoneal Injection 
Three mice were injected intraperitoneally with 200 µl (1 x 107 cfu) S. aureus Xen 36, using size 27 g 
needles.  The mice were imaged for the presence of bioluminescent bacteria before injection, 15 min 
after injection, and again after 2, 4, 24 and 48 h. 
 
Intravenous (Tail Vein and Penile Vein) Injection 
Two animals were infected in the dorsal tail vein and one in the penile vein with 200 µl (1.4 x 108 cfu) 
S. aureus Xen 36, using size 27 g needles.  Veins were dilated by exposure to infrared light.  
Bioluminescent images were taken every 24 h for 120 h. 
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Intramuscular Injection 
The right thighs of two mice were injected with 50 µl (3.6 x 107 cfu) of S. aureus Xen 36, followed by 
another injection 2 h later.  The mice were scanned for the presence of bioluminescent bacteria before 
and immediately after both injections, and 72 and 144 h after the first injection. 
 
Optimizing the Infection Dosage 
Eight mice (two per group) were treated as follows: Mice in group 1 were immune compromised by 
feeding them dexamethazone (2.5 mg/l in drinking water) for a week and then intraperitoneally 
injected with 200 µl (2 x 107 cfu) S. aureus Xen 36.  Mice in group 2, not immune compromised, were 
injected with the same number of S. aureus Xen 36.  Mice in groups 3 and 4 were injected with 200 µl 
S. aureus Xen 36, containing 1 x 108 cfu and 4 x 108 cfu, respectively.  The cell numbers were chosen 
to represent three different levels of infection.  The mice were scanned for the presence of 
bioluminescent bacteria before injection, and 24 h and 72 h after injection. 
 
Treatment with Nisin F 
Six mice were intraperitoneally injected with 200 µl (1 x 108 cfu) S. aureus Xen 36, left for 2 h and 
then treated as follows: Two mice were injected with 200 µl (640 Au) nisin F intraperitoneally, two 
mice were injected with the same concentration nisin F subcutaneously, and two mice were left 
untreated.  The mice were scanned for the presence of bioluminescent bacteria after 2 h of infection 
with S. aureus Xen 36 and then treated with nisin F.  Images were recorded 2, 22 and 46 h after 
treatment with nisin F. 
 
Results 
Spectrum of Antimicrobial Activity (in vitro) 
Growth of S. aureus strains Xen 29, Xen 30, Xen 31 and Xen 36, and L. monocytogenes EGDe were 
inhibited by nisin F, with the best antimicrobial activity recorded against S. aureus Xen 36 (not 
shown). 
 
Intragastric Infection  
No bioluminescence was recorded during the 48 h the mice were scanned (Fig. 1B).  However, 
bioluminescent, thus metabolically active, cells were observed in the feces collected from these mice.  
High numbers (3.3 x 105 cfu/mg feces) of L. monocytogenes EGDe were secreted 8 h after infection 
(Fig. 1A).  S. aureus Xen 36, on the other hand, was mostly secreted (6.2 x 105 cfu/mg feces) 4 h after 
infection (Fig. 1A).  None of the strains were secreted 48 h after infection (Fig. 1A).  Bioluminescent 
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bacteria were also observed in the jejunum, duodenum and ileum of mice 14 days after intragastric 
administration with L. monocytogenes EGDe (not shown). 
 
 
Fig. 1  a Number of viable cells recorded per gram feces collected at specific time points after 
intragastric inoculation with S. aureus Xen 36 (♦) and L. monocytogenes EGDe (■). Values represent 
an average recorded for the six mice in each group.  ▲ control (inoculated with sterile saline).  b 
Bioluminescent image of a mouse after 48 h of intragastric infection with L. monocytogenes EGDe 
and S. aureus Xen 36 
 
Intraperitoneal Infection 
Cells of S. aureus Xen 36 were recorded in the peritoneal cavity immediately after injection (not 
shown) and after 2 h (2.3 x 104 p/s/cm2/sr).  This was followed by more localized infection after 4 h 
(4.2 x 104 p/s/cm2/sr), which gradually changed over the next 44 h.  Average radiance levels of 2.7 x 
104 p/s/cm2/sr were recorded at 24 h and 2.3 x 105 p/s/cm2/sr at 48 h (Fig. 2).  Throughout the course 
of all experiments, a few mice showed no signs of infection over 8 days (shown in Fig. 3A).  
However, when dissected, bioluminescent bacteria were detected in the peritoneal cavity (Fig. 3B), 
associated with the stomach, ileum, duodenum and jejunum, and the heart and kidneys (Fig. 3C). 
 
 
 
A B 
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Fig. 2 Bioluminescence recorded when mice were intraperitoneally injected with 200µl (1x108 cfu) S. 
aureus Xen 36.  Images were recorded over 48 
 
 
 
Fig. 3 Bioluminescence recorded when mice were intraperitoneally injected with 200µl (1x108 cfu) S. 
aureus Xen 36.  a Image taken of a diseased mouse after 8 days of infection.  b The same mouse 
dissected, with the peritoneal cavity exposed. c Individual organs of the same mouse 
 
Intravenous Infection 
Injection of S. aureus Xen 36 in the tail and penile veins resulted in localized tissue infection for the 
first 120 h (results not shown).  Average radiance values for penile vein injection ranged from 1.4 x 
106 p/s/cm2/sr immediately after injection to 1.8 x 105 p/s/cm2/sr 5 days after infection.  Bacteria 
injected into the dorsal tail vein showed an average radiance of 3.5 x 105 p/s/cm2/sr immediately after 
injection to 1.7 x 105 p/s/cm2/sr after 120 h. 
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Intramuscular Infection 
A faint bioluminescent signal of 5.2 x 103 p/s/cm2/sr was recorded immediately after injection of S. 
aureus Xen 36 into the thigh, but lasted for only 15 min.  No bioluminescence was observed after a 
second injection with S. aureus Xen 36 in the same area 2 h later (results not shown). 
 
Optimal Infection Dosage 
No bioluminescent cells of S. aureus Xen 36 were recorded when mice were intragastrically infected 
(not shown).  Clear bioluminescent signals with an average of 1.1 x 104 p/s/cm2/sr were recorded on 
the first day after intraperitoneal injection with 2 x 107 cfu S. aureus Xen 36 (Fig. 4).   
 
 
 
Fig. 4 Mice intraperitoneally infected with S. aureus Xen 36 and imaged over 72 h.  Group 1 Immune 
compromised with dexamethazone (2.5 mg/l drinking water) for a week before infection with 2 x 10
7
.  
Group 2 Not immune compromised and also infected with 2 x 107 cfu.  Groups 3 and 4 Infected with1 
x 10
8
 cfu and 4 x 108 cfu, respectively.  The mice were scanned for the presence of bioluminescent 
bacteria before infection, 15 min after infection and again at 24 h and 72 h 
 
A slightly larger spread of infection, but with more or less the same intensity (9.4 x 103 p/s/cm2/sr), 
was observed in mice that have not been pre-treated with dexamethazone (Fig. 4).  Injection with 
higher cell numbers (1 x 108 cfu and 4 x 108 cfu) of S. aureus Xen 36 resulted in more intense 
           GROUP 1              GROUP 2          GROUP 3         GROUP 4 
0.25 h 
24 h 
72 h 
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infection (1.5 x 104 and 2.4 x 104 p/s/cm2/sr, respectively) of the peritoneal cavity (Fig. 4).  After 96 h, 
bioluminescent images (6.1 x 104 p/s/cm2/sr) were only recorded in mice infected with cell numbers 
higher than 1 x 108 cfu (not shown).  Within 24 h after infection, one of the mice in group 4 died. 
 
Treatment with nisin F 
Since infection could not be accomplished with intragastric, intravenous or intramuscular routes of 
administration, all mice were injected with S. aureus Xen 36 in the peritoneal cavity.  Nisin F injected 
to the same area of infection resulted in a slight decrease from 2 x 106 to 3 x 105 p/s/cm2/sr after 2 h (4 
h, Fig. 5).  Similar results (a decrease from 1.9 x 106 to 2.9 x 104 p/s/cm2/sr) were recorded when nisin 
F was injected subcutaneously.  A slight decrease in infection 1.2 x 106 to 3.6 x 104 p/s/cm2/sr was 
recorded in mice not treated with nisin F, but the levels of infection increased to 1.3 x 105 p/s/cm2/sr 
whilst no ROIs could be recorded for mice that have been treated (24 h, Fig. 5).  However, infection 
slightly re-emerged during the following 24 h (48 h, Fig. 5). 
 
 
 
Fig. 5 Mice infected with S. aureus Xen 36 (1 x 108 cfu) for 2 h, treated with nisin F intraperitoneally 
(i.p.) and subcutaneously (s.c.), respectively, and monitored for 46 h. The arrow indicates nisin F 
administration 
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Discussion 
Nisin F showed more antimicrobial response against S. aureus Xen 36 and L. monocytogenes EGDe 
growth, rendering these two strains the most appropriate to use in in vivo infection studies.  
Staphylococcus aureus Xen 36 and L. monocytogenes EGDe survived conditions in the GIT, as clearly 
indicated by the presence of bioluminescent, and thus metabolically active, cells in the feces collected 
from intragastrically infected mice (Fig. 1).  Staphylococcus aureus Xen 36 was secreted more rapidly 
compared to L. monocytogenes EGDe (Fig. 1), suggesting that L. monocytogenes colonized the gastro-
intestinal tract (GIT) more effectively.  This is not surprising, as S. aureus is more associated with 
topical, airway and systemic infections, whereas L. monocytogenes causes severe food-borne 
infections [3].  Colonization was mostly found in the jejunum and to a lesser extent in the ileum and 
duodenum (not shown), suggesting that conditions in the jejunum are optimal for the survival and 
growth of L. monocytogenes. 
The inability to record bioluminescence of S. aureus Xen 36 and L. monocytogenes EGDe in 
mice that have been infected intragastrically (Fig. 1B) may be due to a number of reasons.  Maximum 
levels of bioluminescence were recorded in the presence of oxygen.  Although expression of the 
luxABCDE operon is not regulated by oxygen, oxygen is required by the luciferase enzyme [4, 23].  It 
may also be that the signal emitted was too low to penetrate through the GIT and the abdomen. 
Of all routes of infection studied, intraperitoneal injection (Fig. 2) proved to be the most 
successful.  The absence of bioluminescence in some mice may be due to a common, unavoidable, 
randomly occurring error in the administration technique where the inoculum ends up subcutaneously, 
in an organ or in the intestines as shown in Fig. 3.  Similar findings have been reported by Steward et 
al. [19], Miner et al. [15], Arioli and Rossi [1] and Das and North [5]. 
Infection of tissue surrounding the tail and penile veins is a clear indication that intravenous 
injection was not successful, most probably due to the small size of the veins.  Based on the results we 
have obtained, cells injected into the thigh muscle are rapidly transferred to other areas, resulting in no 
detection after 15 min.  It is, however, interesting that injection into the same area 2 h later did not 
elicit infection.  The reason for this is not clear and need to be investigated. 
Staphylococcus aureus Xen 36 levels of 2 x 107 cfu caused infection, but lasted for one day 
only (24 h, Fig. 4).  Much higher cell numbers (4 x 108 cfu) is considered lethal, because one of the 
mice died within 24 h after infection.  Cell numbers of 1 x 108 cfu yielded a high bioluminescent 
signal immediately after infection, which was still visible 72 h later (Fig. 4), suggesting that this is the 
initial cell number required for sustainable infection without killing the animal. 
Treating of infected mice with nisin F, either intraperitoneally or subcutaneously, lowered 
the cell numbers during the first 2 h after treatment, as reflected by a decrease in bioluminescence (4 h, 
Fig. 5).  Control of infection was maintained for at least a further 20 h (24 h, Fig. 5), suggesting that 
the cell numbers of S. aureus Xen 36 were too low to emit a readable bioluminescent signal.  Brand et 
al. [2] have shown that a single dosage of nisin F administered in the peritoneal cavity controlled the 
growth of S. aureus for at least 15 min.  Re-appearance of the infection 24 h later (48 h, Fig. 5) 
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suggests that some bacteria became resistant to nisin F or that the activity of nisin F decreased to 
below MIC levels after 46 h in the peritoneal cavity or when injected subcutaneously.  Although no 
significant differences were recorded between infected animals treated intraperitoneally and 
subcutaneously (Fig. 5), intraperitoneal administration is considered more favorable because 
subcutaneous administrated substances are taken up slower due to the presence of lymphatic 
capillaries and regional lymph nodes [17]. Future studies will include prophylactic treatment of mice 
before infection, and also long-term treatment of S. aureus infections to evaluate the therapeutic 
properties of nisin F. 
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Abstract 
Aims: To determine the ability of nisin F to control systematic infection caused by Staphylococcus 
aureus, using C57BL/6 mice as a model. 
Methods and Results: Twelve mice were intraperitoneally injected with 1 x 108 viable cells of Staph. 
aureus Xen 36 containing the modified Photorhabdus luminescence luxABCDE operon on plasmid 
pAUL-A Tn4001.  After 4 h, six mice were intraperitoneally injected with 640 AU (arbitrary units) 
nisin F and six were injected with sterile saline.  Six mice, not infected with Staph. aureus, were 
treated with nisin F and six not infected were left untreated.  The viability of Staph. aureus Xen 36 
was monitored over 48 h by recording photon emission levels.  Nisin F suppressed Staph. aureus for 
15 min in vivo.  No abnormalities were recorded in blood analyses and internal organs of mice treated 
with nisin F. 
Conclusions: Nisin F suppressed the growth of Staph. aureus in the peritoneal cavity for at least 15 
min.  Re-emergence of Staph. aureus bioluminescence over the next 44 h suggests that nisin F was 
inactivated, most probably by proteolytic enzymes. 
Significance and Impact of the Study: A single dosage of nisin F administered in the peritoneal 
cavity controlled the growth of Staph. aureus for at least 15 min in vivo. 
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Introduction 
Staphylococcus aureus causes food poisoning and a number of diseases (Lowy 1998).  The rapid 
emergence of multidrug resistant strains of Staph. aureus (Awad et al. 2007) necessitates the search 
for novel antimicrobial compounds.  Nisin F, a newly described nisin variant produced by Lactococcus 
lactis subsp. lactis, has in vitro activity against Staph. aureus (de Kwaadsteniet et al. 2008). 
 
This study was conducted to determine whether nisin F could be used to control Staph. aureus 
infection in vivo.  The target strain used in the study contains a plasmid with the luxABCDE operon 
that produces luciferase in the presence of ATP (Contag et al. 1995).  Bioluminescence is thus used to 
record metabolic activity.  The same reporter system has been used by Francis et al. (2000) and de 
Kwaadsteniet et al. (2009, 2010). 
 
Materials and methods 
Microorganisms 
L. lactis subsp. lactis F10, producer of nisin F, was cultured at 30°C in De Man Rogosa Sharpe (MRS) 
broth (Biolab, Biolab Diagnostics, Midrand, South Africa).  Staph. aureus Xen 36 (BiowareTM 
Microorganisms, Caliper Life Sciences, Hopkinton, MA, USA) was used as target strain.  Strain Xen 
36, originally isolated from a bacteremia patient and deposited as Staph. aureus ATCC 49525, was 
genetically modified by cloning the luxABCDE operon of Photorhabdus luminescence into a single 
integration site on a native plasmid containing the kanamycin resistance gene (Francis et al. 2000).  
Staph. aureus Xen36 was cultured at 37°C in brain heart infusion (BHI, Biolab), supplemented with 
200 µg ml-1 kanamycin to keep the plasmid under selective pressure.  Active-growing cells were 
harvested (15 300 g, 10 min, 4°C), washed twice with sterile saline (15 300 g, 10 min, 4°C) and 
resuspended in sterile saline to an optical density (A600nm) of 0.4 (measured from a ten-fold dilution). 
 
Preparation of nisin F and in vitro activity tests 
Lactococcus  lactis subsp. lactis F10 was cultured at 30°C in 1 L MRS broth (Biolab) for 18 h.  The 
cells were harvested (11 300 g, 20 min, 4°C) and nisin F precipitated from the cell-free supernatant 
with 80% ammonium sulphate and dialised according to Sambrook et al. (1989).  The peptide was 
concentrated by freeze-drying and suspended in sterile distilled water.  Protein concentration was 
determined using the BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA) and 
antimicrobial activity expressed as AU mg-1 protein.  The purity of nisin F was determined by SDS-
tricine gel electrophoresis, according to Van Reenen et al. (1998). 
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The antimicrobial activity of nisin F was determined by using the agar-spot test method as described 
by de Kwaadsteniet et al. (2008).  Staph. aureus Xen 36 (1 x 106 CFU) was imbedded in BHI soft agar 
(1%, w/v), supplemented with 200 µg ml-1 kanamycin. 
 
Antimicrobial activity of nisin F was also recorded by monitoring changes in bioluminescence of 
Staph. aureus Xen 36.  The strain was grown in BHI broth, supplemented with 200 µg ml-1 
kanamycin, to an optical density (OD600nm) of 1.5.  Wells of a sterile titre plate were filled with 100 µl 
(3 x 107 CFU) of the culture and then treated with two concentrations of nisin F.  Wells A1-3 received 
75 µl (240 AU) nisin F and wells A4-6 150 µl (480 AU) nisin F.  The control received nothing.  
Bioluminescent readings were taken at 490 nm at T0 (before the addition of nisin F), T0.10 (6 min after 
addition), T24 (24 h later) and T48 (48 h later), using the Xenogen In Vivo Imaging System (IVIS
® 100) 
of Caliper Life Sciences.  Living Image® software, version 3.0 (Caliper Life Sciences) was used to 
quantify the average radiances (avg. rad.) of photons emitted from regions of interest (ROIs).  The 
ROI was selected by using the free draw method, with the threshold set at zero percent.  Values 
recorded from each well were expressed as log10 photons second
-1 cm-2 steridian-1 (p s-1 cm-2 sr-1).  The 
correlation between p s-1 cm-2 sr-1 and viable cell numbers (CFU) was obtained from a standard curve.  
For the standard curve, cells were grown in BHI, supplemented with 200 µg ml-1 kanamycin, to an 
optical density (OD600nm) of 1.5, which represented 3 x 10
8 CFU ml-1.  Sterile titre plates were filled 
with 100 µl of the cell suspension (3 x 107 CFU) and incubated at 37°C for 48 h.  At specific time 
intervals the number of photons emitted per second was recorded and converted to p s-1 cm-2 sr-1 by the 
Living Image® software.  The number of viable cells (CFU) was determined by plating onto BHI agar. 
 
Antimicrobial activity of nisin F in vivo 
Approval to conduct this research on mice was granted by the Ethics Committee of the University of 
Stellenbosch (ethics reference number: 2008B02003A2). 
 
C57BL/6 mice weighing between 20 and 30 g were fed a standard rodent diet and kept under 
controlled environmental conditions.  Twenty-four mice were anaesthetized with 2% (v/v) isoflurane 
(Isofor, Safe Saline pharmaceuticals, Florida, South Africa).  Twelve mice were intraperitoneally 
injected with 200 µl (1 x 108 viable cells) of Staph. aureus Xen 36 and divided into two groups of six 
mice each.  After 4 h of infection, mice in group 1 were again anaesthetized and intraperitoneally 
injected with 200 µl nisin F (640 AU).  Mice in group 2 were also anaesthetized, but intraperitoneally 
injected with 200 µl sterile saline.  Images were taken at T0 (before infection with Staph. aureus Xen 
36), T0.25 (15 min after infection), T4 (4 h after infection and immediately before treatment with nisin 
F), T4.25 (15 min after treatment), and T8, T24 and T48 (i.e. 4 h, 20 h and 44 h after treatment with nisin 
F).  Mice in group 3 (not infected with Staph. aureus) were treated with nisin F (640 AU) 4 h after 
infection.  Mice in group 4 were not infected and were not treated with nisin F.  All mice were 
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anaesthetized with the same dosage of isoflurane.  Bioluminescent readings of each were taken with 
the IVIS® 100 at 490 nm, as described before.  The avg. rad. of mice in each group was calculated.  
Where no ROIs could be detected, values of 0 were changed to 0.001 to allow for log10 calculations. 
 
Histology 
At the end of the two-day experiment the mice were sacrificed by cardiac puncture after an overdose 
of sodium pentobarbitone (Euthanaze, Centaur Labs) administered intraperitoneally.  Samples of the 
intestinal tract, heart, liver, kidneys, lungs and spleen were kept in 4% (v/v) formaldehyde (PBS) for 
24 h at 25ºC, embedded in paraffin, sectioned and then stained with hematoxylin and eosin (H&E).  
Microscopic analysis was done at Pathcare Veterinary Pathologists (Pathcare, Dietrich, Voigt, Mia and 
Partners, Goodwood, South Africa). 
 
Statistical Analysis 
Mixed model repeated measures ANOVA was used to determine the effects of treatments over time on 
results presented in Fig.1 and Table 1. 
 
Results 
In vitro activity of nisin F 
Nisin F prepared from an 18-h-old culture yielded 3 200 AU ml-1, as recorded with the agar-spot 
method.  This correlated to 66.72 AU mg-1 protein.  Separation by SDS-tricine PAGE yielded a single 
protein band of 3.5 kDa (not shown), corresponding to the 3 457 Da reported for nisin F (de 
Kwaadsteniet et al. 2008).  Bioluminescent readings recorded for Staph. aureus Xen 36 treated with 
240 AU nisin F (A1-A3) and 480 AU nisin F (A4-A6) changed from 5.75 p s-1 cm-2 sr-1 (3 x 107 CFU) 
before treatment to 4.80 p s-1 cm-2 sr-1 (2.5 x 107 CFU) within 6 min (not shown).  On the other hand, 
bioluminescence of the control group (B1-B6), not treated with nisin F, increased from 5.76 p s-1 cm-2 
sr-1 (3 x 107 CFU) to 5.92 p s-1 cm-2 sr-1 (3.1 x 107 CFU) over the same period and to approximately 
6.30 p s-1 cm-2 sr-1 (3.3 x 107 CFU) over the next 48 h (not shown).  Results recorded for Staph. aureus 
Xen 36 treated with nisin F differed significantly (p  0.01) from Staph. aureus Xen 36 not treated 
with nisin F (not shown).  A decrease in photons indicates that either fewer Staph. aureus cells are 
present or that the cells present are not metabolically active. 
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In vivo activity of nisin F 
Bioluminescent images recorded for a representative mouse from each of the 4 groups is shown in Fig. 
1.   
 
 
Figure 1 Bioluminescent images of selected mice from different groups.  Group1: infected with 1 x 
108 viable cells of Staph. aureus Xen 36 for 4 h, treated with 640 AU nisin F, and monitored for a 
further 44 h.  Group 2: infected with the same number of Staph. aureus Xen 36 for 4 h, but treated 
with sterile saline after 4 h.  Group 3: Not infected with Staph. aureus Xen 36 and treated with 640 
AU nisin F.  Group 4: Not infected and not treated.  Arrows indicate time of infection and treatment.  
Bioluminescence emitted from regions of interest (ROI) was measured as p s-1 cm-2 sr-1 and the total 
average radiation for each mouse calculated.  Readings are listed in Table 1.  Symbols: * = infection, † 
= treatment. 
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Mice injected with Staph. aureus Xen 36 (groups 1 and 2) showed clear signs of infection in the upper 
and lower sections of the peritoneal cavity after 15 min of inoculation (T0.25, Fig. 1).  In both groups 
the infection increased over the next 3 h and 45 min, as observed by changes in photon counts (Table 
1).   
 
Table 1  Log10 values of average radiance (p s
-1 cm-2 sr-1) measured from ROIs in bioluminescent 
images.  Values listed are the average recorded for six mice in each group 
Group* Time (h) 
 0.25 4.00 4.25 8.00 24.00 48.00 
1 3.87 ± 0.28 4.73 ± 0.26 4.55 ± 0.22 4.55 ± 0.25 4.04 ± 0.32 4.17 ± 0.36 
2 3.85 ± 0.21 4.88 ± 0.21 4.90 ± 0.20 4.64 ± 0.53 3.48 ± 0.38 3.50 ± 0.54 
 
*Group 1: infected with Staph. aureus Xen 36 and treated with nisin F. 
 Group 2: infected with Staph. aureus Xen 36 and treated with sterile saline (control). 
Variations recorded between the different readings are indicated by ± values. 
 
Fifteen minutes after treatment with nisin F (T4.25), Staph. aureus bioluminescence in the mid to upper 
section of the peritoneal cavity decreased slightly (an average decrease in photons from 4.73 to 4.55 p 
s-1 cm-2 sr-1; Table 1).  At the same time interval, bioluminescence in the lower section of the peritoneal 
cavity, closer to the tail, was slightly suppressed (group 1, Fig. 1).  Staph. aureus bioluminescence 
gradually decreased over the following 20 h in mice treated with nisin F (Table 1), but 
bioluminescence re-emerged 24 h later, specifically in the mid to upper section of the peritoneal cavity 
(T48, Fig. 1).  Levels of Staph. aureus bioluminescence in mice treated with saline (group 2) remained 
unchanged for 4 h (up to T8), decreased over the next 16 h (T24), but re-emerged 24 h later (T48) in the 
mid to upper section of the peritoneal cavity (Fig. 1, Table 1). There were overall no significant 
differences (p = 0.48) observed between mice treated with nisin F and mice treated with sterile saline.  
However, a more significant difference in bioluminescence (post hoc p value of 0.26) has been 
recorded 15 min after administration of nisin F (Fig. 2). 
 
Histology 
Lymphoid hyperplasia was observed in the spleen samples of mice from all four groups. Infiltration of 
polymorphonuclear cells and mild degenerative changes of hepatocytes were observed in the livers of 
mice from groups 1 and 2 (not shown).  Segmented filamentous bacteria were observed in various 
sections of the intestinal tract of mice in groups 1 and 2 (not shown). 
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Figure 2 No significant differences (p = 0.48) were recorded between mice treated with nisin F 
(plotted as ––) and mice treated with sterile saline (plotted as ––).  However, according to the post 
hoc value (p = 0.26) of results 15 min after administration of nisin F, a significant difference has been 
recorded.  The data used is from Table 1.  Vertical bars denote 0.95 confidence intervals of Least 
Squares (LS) means.  Letters indicates significant differences on a 5% level (p<0.05) for the post hoc 
tests.  Where associated letters are different (no letters overlap), the difference is significant.  Where at 
least one letter appears above both of the means to be compared, the difference is not significant. 
 
Discussion 
Nisin F inhibits a number of Gram-positive bacteria (de Kwaadsteniet et al. 2008) and proved 
successful in the treatment of Staph. aureus infection in the respiratory tract of Wistar rats (de 
Kwaadsteniet et al. 2009). However, nisin F could not control subcutaneous infections caused by 
Staph. aureus (de Kwaadsteniet et al. 2010).  Based on these results, the authors hypothesised that the 
innate immune system of mice has been more successful in combating the infection, or that 
administration of nisin F could have modulated the innate immune system. 
 
Readings recorded with  the IVIS® 100 indicated that all cells of Staph. aureus Xen 36 have lost their 
bioluminescence within 6 min of treatment with either 240 AU or 480 AU nisin F, with no recovery 
towards the end of the 48 h experiment.  This suggests that 240 AU nisin F is sufficient to suppress 
cell growth in vitro for at least 48 h. 
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Nisin F suppressed a certain percentage of Staph. aureus Xen 36 for up to 15 min in the peritoneal 
cavity (Table 1).  Furthermore, the re-emergence of Staph. aureus Xen 36 bioluminescence 44 h after 
treatment suggests that the peptide has been degraded or inactivated, possibly by proteolytic enzymes, 
or that the strain became resistant to nisin F.  Overall, bioluminescence of the cells decreased, but was 
not eliminated.  This suggests that the mode of activity of nisin F against Staph. aureus Xen 36 is 
bacteriostatic in vivo.  Photon emission readings were taken from the same animal over a short time 
period (48 h).  Thus, changes in p s-1 cm-2 sr-1 readings recorded are directly related to the physiological 
state of strain Xen 36 in a specific animal and are not influenced by changes in body mass.  It is 
important to realise that photons emitted from strain Xen 36 lose signal strength as they migrate 
through the tissue.  Thus, contrary to readings taken in vitro, photons emitted in vivo are indirectly 
related to the level of infection, but no direct correlation can be drawn between photons emitted (p s-1 
cm-2 sr-1) and number of viable cells of strain Xen 36 in situ. 
 
Growth of segmented filamentous bacteria (SFB) in the intestinal tract could be due to secondary 
infection induced by Staph. aureus.  Growth of these bacteria in the gastro-intestinal tract could not be 
controlled with nisin F, suggesting that the peptide did not migrate across the epithelial cells and 
mucus of the intestinal wall, or that the SFB are resistant to the lantibiotic.  The peptide could also 
have been degraded.  These bacteria naturally colonize the intestinal tract of rodents and their numbers 
often increase in response to the presence of a pathogen (Davis and Savage 1974).  Snel et al. (1995) 
described SFB as autochthonous, strictly anaerobic, spore-forming, Gram-positive bacteria 
representing a cluster within the Clostridium subphylum and proposed the name “Candidatus 
Arthomitus”.  These bacteria may stimulate the formation of intraepithelial lymphocytes (Umesaki et 
al. 1995; Talham et al. 1999) and lead to an increase in the mucosal immune system (Klaasen et al. 
1993; Umesaki et al. 1995).  No visible abnormalities were observed in any of the organs that have 
been studied.  This, however, does not rule out the possibility of cell damage or mutations that could 
have taken place. 
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Abstract 
Mice were intraperitoneally infected with 2 x 108 cfu Staphylococcus aureus Xen 36 and treated with 
2130 AU (arbitrary units) Nisin F, a class Ia lantibiotic, over seven days.  Nisin F was delivered at a 
constant rate to the intraperitoneal cavity by using osmotic minipumps.  The metabolic activity of S. 
aureus Xen 36, concluded from changes in cell bioluminescence, declined for the first 3.5 h, but 
increased over the next 24 h and remained constant during the rest of the trial.  Similar results were 
obtained with inactive (autoclaved) nisin F.  This suggests that the decline in metabolic activity of S. 
aureus Xen 36 was not due to the presence of nisin F.  The drastic increase in neutrophil versus 
lymphocyte numbers (N:L ratio) observed in mice infected with S. aureus Xen 36 and treated with 
nisin F, opposed to mice not infected and treated with nisin F, suggested that the decline in metabolic 
activity of S. aureus Xen 36 was due to an immune response triggered by the infection. In uninfected 
mice, treatment with nisin F elicited increased plasma IL-6 and decreased IL-10 levels and the 
magnitude of these responses was significantly larger in the group treated with active nisin F when 
compared to inactive nisin F. However, the overall immune response triggered by nisin F was too 
small to suggest an antigenic immune reaction.  
 
Keywords: bioluminescence, Staphylococcus aureus, immune response 
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1. Introduction 
Staphylococcus aureus is a normal inhabitant of the human skin, nose and mucosal surfaces, but some 
strains may cause serious infections and even death if cell numbers are not controlled [1].  The 
prevalence of methicillin-resistant strains of S. aureus (MRSA) in hospitals and the community is of 
global concern and the need to discover novel antimicrobial compounds is of critical importance.  
Nisin F, a class Ia lantibiotic, showed promising results in the treatment of respiratory tract [2] and 
intraperitoneal [3] infections, but not in subcutaneous infections [4].  A single dosage of nisin F 
injected into the intraperitoneal cavity suppressed the metabolic activity of a bioluminescent strain of 
S. aureus (strain Xen 36) for at least 15 min [3].  The subsequent increase in bioluminescence was 
ascribed to the possible degradation of nisin F by proteolytic enzymes or acquired resistance to the 
treatment [3].  Nisin F incorporated into bone cement prevented the growth of S. aureus Xen 36 in 
vivo [5].  Although these studies have shown that nisin F may be used to treat S. aureus infections, 
little is known about the effect the lantibiotic has on the immune system. 
 
In this study, nisin F was administered in vivo to BALB/C mice over 7 days.  A constant flow of nisin 
F was delivered into the peritoneal cavity by subcutaneously implanted osmotic minipumps.  These 
osmotic pumps have been used for more than 40 years for the delivery of various compounds 
including antibodies, cytokines, growth factors, neurotrophic factors, insulin and numerous proteins. 
To our knowledge this is the first time these pumps were used to deliver a bacteriocin. Implementation 
of the pumps has various advantages over repeated manual administration, especially in the case of 
proteins and peptides with short half-lives. Advantages include a maintained therapeutic level 
throughout the study, convenience, minimized experimental variables, reduced handling and stress to 
laboratory animals and delivery of agents to most bodily sites. 
 
Changes in the immune system of mice in response to nisin F were monitored by differential blood 
counts (total white blood cells, neutrophils, lymphocytes, monocytes, eosinophils and basophils) and 
by determining the levels of interleukin-6 (IL-6), interleukin-10 (IL-10), monocyte chemoattractant 
protein-1 (MCP-1), interferon-γ (IFN-γ), tumor necrosis factor (TNF) and interleukin-12p70 (IL-
12p70) in plasma of blood sampled from non-infected mice.  These are the most important cytokines 
(immunomodulating cell-signalling molecules produced by white blood cells, but also various other 
cell types) involved in the inflammatory response in mice and were therefore chosen for assessment. 
In addition, changes in the metabolic activity (bioluminescence) of S. aureus Xen 36 was monitored in 
mice treated with either active or inactive (autoclaved) nisin F. 
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2. Materials and methods 
2.1 Preparation of nisin F  
Lactococcus lactis subsp. lactis F10, producer of nisin F, was cultured at 30ºC in De Man Rogosa 
Sharpe (MRS) broth (Biolab, Biolab Diagnostics, Midrand, South Africa), as described by Brand et al. 
[3].  Cells were harvested at 11300 x g (20 min, 4°C).  Nisin F was precipitated from the cell-free 
supernatant with 80% saturated ammonium sulphate [6] and dialysed against sterile distilled water 
through a 1000 Da cut-off regenerated cellulose membrane (Spectra/Por®, Spectrum Laboratories, Inc. 
Rancho Dominguez, CA, USA).  The dialysate was concentrated by freeze-drying and then 
redissolved in sterile distilled water.  The antimicrobial activity of nisin F was determined using the 
agar spot-test method [7] and expressed as AU (arbitrary units) per mL.  Staphylococcus aureus Xen 
36, cultured at 37°C in Brain Heart Infusion (BHI, Biolab Diagnostics) supplemented with 200 µg/mL 
kanamycin, was used as target strain. 
 
2.2 In vivo antimicrobial activity and immunological effect of nisin F 
2.2.1 Preparation of osmotic minipumps and polyethylene tubing 
Active nisin F (200 µL per pump, equivalent to 2130 AU) and the same volume of inactivated 
(autoclaved) nisin F were injected into Alzet® model 2001 osmotic minipumps (Durect, Cupertino, 
CA, USA).  The outer surfaces of the minipumps were sterilized by wiping the outside surface with 
70% (v/v) isopropanol. Pumps were placed in sterile petri dishes and incubated at 37°C for 24 h to 
initialise capillary flow.  Sterile polyethylene tubing was attached to the flow moderators of 
minipumps to deliver nisin F directly into the peritoneal cavity. To prevent adherence of S. aureus Xen 
36 to the outer surface of the polyethylene tubing, the tubing was coated with a thin layer of nisin F 
(10650 AU/mL), encapsulated in a combination of poly (D-L) lactide dissolved in dimethylformamide 
(20% w/v).  Inactive nisin F served as control.  Three coatings of the nisin F-imbedded polymer were 
applied, with 2 h of drying (at room temperature) in between.  The coated tubes were left in a laminar 
flow cabinet overnight to dry at room temperature before they were attached to minipumps and 
surgically implanted into the mice. 
 
2.2.2 Infection with S. aureus and treatment with nisin F 
Ethical approval was granted by the Ethics Committee of the University of Stellenbosch (reference 
number: 10NMDIC01). 
 
Twenty-four BALB/c mice (20 to 30 g each) were divided into four equal groups and housed in 
sterilized type II short filter cages under controlled environmental conditions.  The mice had free 
access to water and feed and were anaesthetised with 2% (v/v) isofluorane (Isofor Safeline 
Pharmaceuticals, South Africa) before all injections or imaging.  On day two, the intraperitoneal 
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cavities of mice in groups 1 and 2 were infected with 200 µL (2 x 108 cfu) S. aureus Xen 36, as 
described previously [3].  Four hours later, minipumps filled with 200 µL (2130 AU) nisin F were 
surgically implanted in a subcutaneous pocket on the dorsal side of mice in group 1.  Mice in group 2 
received minipumps filled with 200 µL inactivated nisin F.  The procedure was repeated on two other 
groups of mice (groups 3 and 4, respectively) that were not infected with S. aureus Xen 36. The 
polyethylene tube attached to each minipump was inserted through a small incision made in the 
peritoneum.  Peritoneum and skin incisions were closed with CliniSorb 1.5 (4/0) sutures (CliniSut, 
Akacia health, Port Elizabeth, South Africa) and the skin wounds sterilized with 10% (v/v) Betadine® 
(Purdue Products L.P., Stamford, CT, USA).  Mice were injected with the analgesic Temgesic 
(Schering-Plough, Woodmead, South Africa), 0.03 mg/kg bodyweight, immediately after surgery and 
12 h later. 
 
2.2.3 Bioluminescent imaging 
Bioluminescent images were recorded with an In Vivo Imaging System (IVIS® 100, Caliper Life 
Sciences, Hopkinton, MA, USA).  All mice were imaged at the same time points, i.e. before infection 
with S. aureus Xen 36, 15 min, 3.5 h, 8 h and 24 h after infection, and every 24 h thereafter for a 
further 6 days.  Photons were quantified by manually selecting the border of each mouse and defining 
the whole body as a region of interest (ROI).  Images were captured after 5 min of exposure, analysed 
with Living Image® software (Caliper Life Sciences) and expressed as average radiance 
(photons/cm2/second/steridian) per ROI.  After 7 days of monitoring the mice were killed by cardiac 
puncture after an overdose of sodium pentobarbitone (Euthapent, Kyron Laboratories, Benrose, South 
Africa). 
 
2.2.4 Immunological analyses 
Blood (ca. 250 µL) was collected from the ventral tail vein of mice in all four groups on days 1, 3, 4, 6 
and 8.  Blood samples were collected in paediatric K2EDTA Vacutainer
® tubes (BD Diagnostics, 
Franklin Lakes, NJ, USA).  Within 4 h after collection, full blood counts were determined using an 
automated hematology analyser (Cell-Dyn 3700 CS, Abbott Diagnostics, Santa Clara, California, 
USA) and analysed with HEMO VetSoft v. 1.1 (Veterinary Software, Davis, CA, USA).  The 
remaining blood samples were centrifuged (1500 x g, 10 min, 25ºC) and the plasma stored at –80°C.  
The effect of nisin F and inactive nisin F on the cytokine (IL-6, IL-10, MCP-1, IFN-γ, TNF and IL-
12p70) levels of uninfected mice (groups 3 and 4) was determined using the BD Mouse Inflammation 
cytometric bead array (CBA) kit (BD Diagnostics).  The cytokine levels of infected mice were not 
analysed, since we were interested in the effect nisin F (active and inactive form) has on the immune 
response in the absence of additional antigenic agents. 
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2.3 Data analyses 
Data was analysed with Statistica software (v.10, StatSoft Inc, OK, USA).  For bioluminescent data, t-
tests assuming unequal variances were performed.  Results for blood parameters were analyzed for 
effects of time and treatment using repeated measures ANOVA or one-way ANOVA with Bonferroni 
post hoc testing.  P-values < 0.05 were considered as significant. 
 
3. Results 
 
3.1 Effect of nisin F on S. aureus Xen 36 
The average radiance (photons/cm2/second/steridian) values recorded for the six mice in group 1 
(infected with S. aureus Xen 36 and treated with nisin F) and the six mice in group 2 (infected with S. 
aureus Xen 36 and treated with inactive nisin F), is shown in Fig. 1.   
 
 
 
Fig. 1. Bioluminescent readings (photons/cm2/second/steridian) recorded from mice infected with S. 
aureus Xen 36 and then treated with nisin F for the following 7 days.  Readings were taken before 
infection (not shown) and 15 min, 3.5 h, 8 h and 24 h after infection, and every 24 h thereafter for a 
further 6 days.  Each data point is an average of readings recorded for six mice in each group.  --♦-- = 
mice infected with S. aureus Xen 36 and treated with nisin F (group 1), ∙∙■∙∙ = mice infected with S. 
aureus Xen 36 and treated with inactive (autoclaved) nisin F (group 2).  Nisin F was injected via 
surgically implanted Alzet osmotic minipumps on day 2, 4 h after infection with S. aureus Xen 36.  
The point at which nisin F was injected is indicated by *. 
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No significant differences in bioluminescence were recorded between the two treatments.  One mouse 
in group 1 and three mice in group 2 died within 24 h after infection.  Since mice in groups 3 and 4 
were not infected with S. aureus Xen 36, no bioluminescence was observed. 
 
3.2 Immune response 
Total white blood cell, monocyte, eosinophil and basophil counts were on average within normal 
ranges, irrespective of the treatment (results not shown).  On day 3, 24 h after infection with S. aureus 
Xen 36, the relative neutrophil count in group 1 mice increased from 23% to 53%, which represents an 
average increase of 130% (Fig. 2A).   
 
 
Fig. 2. Distribution of neutrophils and lymphocytes in mice recorded on day 1 (before infection with 
S. aureus Xen 36), on day 3 (24 h after infection), and on days 4, 6 and 8. Mice in groups 1 and 3 were 
infected with S. aureus Xen 36 on day 2. ■ = group 1 (infected with S. aureus Xen 36 and treated with 
nisin F), ■ = group 2 (infected with S. aureus Xen 36 and treated with inactive nisin F), □ = group 3 
(not infected and treated with active nisin F), ■ = group 4 (not infected and treated with inactive nisin 
F).  Data are presented as mean ± SD (n=6/group). Values without common post hoc letters (a-e) 
differ significantly (p < 0.05). 
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On the same day, the relative neutrophil count in mice of group 2 increased from 22% to 67%, which 
represents an increase of 200% (Fig. 2A).  On day 4, the relative neutrophil count of group 1 mice 
increased to a similar level (approximately 65%) as that recorded for group 2 mice (Fig. 2A).  The 
neutrophil count of mice in both groups remained at more-or-less this level for the next four days.  The 
neutrophil levels of mice in groups 3 and 4 basically remained the same throughout the trial (Fig. 2A).   
 
One day after infection with S. aureus Xen 36, the relative lymphocyte count in group 1 mice 
decreased from 70% (day 1) to 43% (day 3), which represents a decrease of 39% (Fig. 2B).  The 
lymphocyte count in group 2 mice decreased from 69% (day 1) to 25% (day 3), which represents a 
decrease of 64% (Fig. 2B).  On day 4, the relative lymphocyte count of group 1 mice decreased to 
almost the same level (27%) as that recorded for group 2 mice (25%, Fig. 2B).  The lymphocyte count 
of mice in both groups remained at this level for the next four days (Fig. 2B).  No significant 
differences in lymphocyte counts were recorded in mice not infected with S. aureus Xen 36, 
irrespective of whether they received active nisin F (group 3) or inactive nisin F (group 4) (Fig. 2B).   
 
The leukocyte response expressed as a ratio between neutrophil and lymphocyte counts (N:L) is 
shown in Fig. 2C.  The N:L values of mice in group 2 was exactly double compared to that recorded 
for mice in group 1 on day 3, i.e. 24 h after infection with S. aureus Xen 36 (Fig. 2C).  However, on 
day 4, the N:L values in both groups were similar and remained more-or-less equal over the following 
four days (Fig. 2C).  No significant differences in N:L levels were recorded between mice not infected 
with S. aureus Xen 36, irrespective of whether they received active nisin F (group 3) or inactive nisin 
F (group 4; Fig. 2C).  
 
Significant changes from baseline levels (day 1) were observed on day 3 and 4 for all cytokines tested 
(Fig 3).  Most notably, the average levels of IL-6 in group 3  mice increased from 10.1 pg/mL on day 1 
to 30.85 pg/mL within 24 h of nisin administration, and remained similar (32.6 pg/mL) on day 4. The 
IL-6 levels in group 4 mice showed a slow, but sustained, increase from 7.9 pg/mL to 19.8 pg/mL on 
day 3, and 19.1 pg/mL on day 4. In contrast, average levels of IL-10 decreased in mice of groups 3 and 
4, but to a lesser extend in mice of group 4.  The MCP-1 levels in group 3 decreased with 31.38  ± 
40.9 %, whilst that in group 4 increased to 16.2 ± 16.7 % from baseline (day 3).   
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Fig. 3. Percentage change from baseline (day 1) in plasma levels of IL-6, IL-10, MCP-1, IFN-γ, TNF 
and IL-12p70 in mice on days 1, 3 and 4.  Results are the average calculated for six mice in each 
group.  □= not infected with S. aureus and treated with active nisin F (group 3), ■= not infected with 
S. aureus and treated with inactive nisin F (group 4).  Values are displayed as means ± SD and values 
with uncommon letters (a-e) differ significantly (p<0.05). 
 
4. Discussion 
In a previous study [3], we have shown that a single dose of nisin F (640 AU) to the intraperitoneal 
cavity reduced the metabolic activity of S. aureus Xen 36 (1 x 108 cfu) for 15 min, but that some cells 
survived the treatment and that their metabolic activity increased over the next 48 h.  The conclusion 
drawn by Brand et al. [3] was that the short-lived antimicrobial effect of nisin F could be attributed to 
degradation of the peptide by proteolytic enzymes in the peritoneal cavity.  With the design of the 
present study, we have argued that the continuous administration of nisin F to the peritoneal cavity 
may effectively repress the growth of S. aureus for a longer period.  Although the metabolic activity of 
S. aureus Xen 36 declined for the first 3.5 h after treatment with nisin F, which is longer than the 15 
min recorded by Brand et al. [3], the cells recovered and, after two days, their metabolic activity 
increased to a level equivalent to that before treatment (Fig. 1).  Similar results were recorded when 
the infection was treated with inactive nisin F (p > 0.05) (Fig. 1).  These results suggested that the 
initial growth inhibition of S. aureus Xen 36 was not due to the antimicrobial activity of nisin F, but 
rather an immune response triggered by the bacterial cells.  This contradicts our previous findings [3], 
namely that nisin controlled the growth of S. aureus Xen 36 in the peritoneal cavity for as long as the 
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peptide remained intact, in other words not degraded by proteolytic enzymes.  Concluded from the 
results in Fig. 1, the immune system showed transient efficiency/activation, lasting only 3.5 hours. 
 
The reason why nisin F did not repress the metabolic activity (and thus growth) of S. aureus Xen 36 is 
not clear.  Nisin F could have been degraded by proteolytic enzymes, as speculated by Brand et al. [3].  
A variety of nisin resistance mechanisms have been described, which includes degradation by 
proteolytic enzymes, the export of nisin by ATP-binding cassette (ABC)-transporters and the 
acquisition of resistance genes from other bacteria [8,9].  A nisin resistance (NSR) protease has been 
described for Lactococcus lactis [10] and a glutamate decarboxylase (gad)-mediated nisin resistance 
enzyme for Listeria monocytogenes [11].  We did, however, not test for the presence of these enzymes 
in S. aureus Xen 36.  Another possibility is that S. aureus Xen 36 could have adhered to the epithelial 
cells to form a protective biofilm within the first 4 h before nisin F was injected into the peritoneal 
cavity.  The biofilm could have lasted throughout the 6-day trial.  It is also possible that nisin F had 
been encapsulated by mucus or other proteins in the peritoneal cavity, as suggested by Breukink and 
de Kruijff [8] and Rink et al. [9]. Another possibility could be that a higher dosage of nisin F is needed 
to overcome bacterial infection in the complex immunological environment in vivo. 
 
Changes recorded in the neutrophil counts suggest that the immune response was activated during the 
first 24 h after infection with S. aureus Xen 36 (groups 1 and 2, day 3, Fig. 2A).  The neutrophil 
counts of mice in groups 1 and 2 did not differ significantly (Fig. 2A), suggesting that active and 
inactive nisin F elicited the same immune response.  The neutrophil counts in uninfected mice treated 
with active and inactive nisin F (groups 3 and 4, respectively), were much lower compared to results 
recorded for infected mice and remained at more-or-less the same level throughout the 7-day trial (Fig. 
2A).  This suggested that the activation of neutrophils (increase in counts) was not due to a response to 
nisin F, but rather due to a response to the infection caused by S. aureus Xen 36.  
 
In contrast, lymphocytes seemed to exhibit effects in response to both bacterial infection and nisin F. 
Firstly, the decline in relative lymphocyte counts from pre-infection with S. aureus Xen 36 (day 1, Fig. 
2B) to 24 h after infection on day 2 and treatment with nisin F (groups 1 and 2, day 3, Fig. 2B) may be 
due to apoptosis.  This is usually observed in the case of severe infection [12].  A decrease in 
lymphocytes may limit the production of pro-inflammatory cytokines, which in turn leads to a decline 
in the defence against a pathogen.  The lymphocyte counts were much higher and constant in mice that 
have not been infected with S. aureus Xen 36 (groups 3 and 4, Fig. 2B), and also similar to pre-
infection counts in mice infected with S. aureus Xen 36 (groups 1 and 2, Fig. 2B).  Treatment of non-
infected mice with active and inactive nisin F had no effect on lymphocyte counts (groups 3 and 4, 
Fig. 2B).  This proved that the major decrease in lymphocyte counts observed in infected mice was 
due to the presence of S. aureus Xen 36.  Of interest, however, is that the infection-associated decline 
in lymphocyte counts were of smaller magnitude after treatment with active nisin F, compared to 
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inactive nisin F.  This may indicate that nisin F somehow limited the sepsis-induced apoptosis of 
lymphocytes. 
 
The N:L ratio provides an accurate indication of bacterial infection, as observed with studies on 
bacteraemia [13].  Similar to the lymphocyte response, the N:L ratio calculated for mice that have not 
been infected with S. aureus Xen 36, but treated with active and inactive nisin F (groups 3 and 4, 
respectively) remained constant throughout the 7-day trial (Fig. 2C).  However, infected animals had 
hugely increased N:L ratio, although this response was also attenuated (to the benefit of the host) in 
animals treated with active nisin F (Fig. 2C).  The overall immune cell data suggests that not only did 
nisin F not have any detrimental effect on the immune system, but that it may have protective benefits 
to this system. 
 
Statistically significant effects of the treatment was seen up to day 4 for cytokines IL-6, IL-10, MCP-1 
and IFN-γ and up to day 3 for TNF and IL-12-p70 (Fig. 3).  The drastic increase in IL-6 levels of 
uninfected mice treated with active nisin F (Fig. 3) suggests that the lantibiotic did initiate some 
degree of an immune response.  The increase in IL-6 levels recorded in the presence of inactive nisin F 
was, however, not that profound (Fig. 3).  The increase in IL-6, together with a decrease in IL-10 and 
TNF levels, suggests that nisin F had an immune boosting effect. Heat treatment breaks the disulphide 
bridges of nisin [14] and changes the tertiary structure.  Concluded from the results shown in Fig. 3, 
nisin F elicits a stronger immune response in terms of IL-6 release when intact.  However, the data 
presented here suggests that nisin F in its active form may also trigger an IL-6 response. This could be 
through protection of lymphocytes (allowing them to produce IL-6) in an infection situation, as seen in 
Fig. 2.  Recently, nisin Z was shown to modulate the innate immune system through the stimulation of 
IL-6 production, together with various other cytokines including MCP-1, IL-8 and Gro-α in human 
peripheral blood mononuclear cells (PBMCs) ex vivo [15]. Through immunomodulatory stimulation, 
the peptide (200 µg/mouse) was also able to protect mice against S. aureus (2 x 108 cfu/mouse) and 
Salmonella typhimurium (2 x 104 cfu/mouse) infections. 
 
In conclusion, nisin F, active or inactive, presented a mild immune boosting effect as indicated by IL-
6, IL-10 and TNF levels.  The overall immune response triggered by nisin F (administered at 2130 AU 
over 7 days) was, however, too small to suggest that an inappropriate immune reaction of clinical 
relevance would occur in the absence of infection.   The fact that inactive nisin F has the same effect 
on the metabolic activity of S. aureus Xen 36 than active nisin F is a clear indication that nisin F has 
no ability to directly control S. aureus infection in the peritoneal cavity.  
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Abstract 
Antimicrobial peptides from various origins, including human, animal, fungal and bacterial, have 
protective properties. Nisin, a lantibiotic, has been used as preservative in the food industry for 
decades. Recently, nisin has also been evaluated as an antibacterial agent in the control of infections. 
Here we evaluated the ex vivo functional capacity of rat peripheral blood mononuclear cells (PBMCs) 
through interleukin-1β (IL-1β) and IL-6 production in response to exogenous stimulus (LPS from 
Escherichia coli) and three nisin variants: nisin F, nisin A and a commercially purified form of nisin 
A, Nisaplin®. The effect of rat serum on the antimicrobial activity of the three variants was also 
analysed with a newly developed multi-well bioluminescence assay. The antimicrobial activity of 
nisin F and nisin A decreased within 10 h of exposure to 40 and 80% (v/v) serum.  The activity of 
Nisaplin®, however, remained unchanged after 18 h in the presence of serum. Nisin F induced IL-1β 
secretion in PBMCs in a dose-dependent manner and at high concentration (5 x MIC) led to a decrease 
in the number of viable lymphocytes (cell counts decreased with 82%, without LPS, and 90% with 
LPS). No significant effect of treatment or dosage was observed for Nisin A or Nisaplin®. These 
results suggest that the in sera effect of nisin is influenced by the preparation of the peptide and that 
nisin-induced cytotoxicity is variant-dependent.  
 
Keywords: nisin, PBMCs, cytotoxicity, serum, bioluminescence 
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Introduction 
Nisin is a lantibiotic, defined as small ribosomally synthesized, posttranslationaly modified class I 
bacteriocin [1]. Nisin A in purified form, commercially distributed as Nisaplin®, is used as food 
preservative.  Nisin F is structurally similar to nisin A [1] and is also produced by Lactococcus lactis 
subsp. lactis.  Nisin is active against Staphylococcus aureus and Listeria monocytogenes and has been 
studied for its application in the medical field [2-4]. 
 
Nisin F controlled S. aureus infection in mice for 15 min after one intraperitoneal (i.p.) administration 
[4].  Continuous administration of nisin F to the i.p. cavity failed to alleviate S. aureus infection, 
despite an increase in immune response elicited by the lantibiotic [5].  The reason for this is not 
entirely clear. Althought it is an important aspect of drug development, only a limited number of 
studies have been conducted on the immune response of bacteriocins.  Cytotoxicity studies have been 
done on the bacteriocins pediocin PA-1 [6,7], divercin V41 [8], carnobacteriocins Cbn BM1 and B2 
[9], the antimicrobial peptides P40 [10] and P34 [11,12], nisin A [13-16] and nisin Z [17].  The 
immunomodulatory effect of nisin A [18,19] and nisin Z [17] has been studied and variable results 
were obtained, which suggests that no general assumptions can be made regarding immune 
modulation.  
 
It is also important to investigate the degree of protein binding (PB) during drug development [20]. PB 
has two main negative effects on in vivo drug efficiency. Firstly, only the unbound fraction penetrates 
the site of infection [21] and is cleared from the body [22]. Secondly, PB can have a detrimental effect 
on the antimicrobial activity of a drug (20,23-25). Various methods have been used to determine the 
degree of PB.  Parameters that should always be taken into consideration are growth media, 
concentration of the antimicrobial agent, temperature, pH, electrolytes and supplements [26]. Current 
PB assays involve either the study of bacterial growth (CFU/ml) at different time points that is 
laborious, or minimum inhibitory concentration (MIC) testing that can be less accurate [26]. The 
method we have developed allows the simultaneous reading of 96 samples over an extended period. 
According to the National Committee for Clinical Laboratory Standards (NCCLS) guidelines [27], a 
drug should be able to exert its antimicrobial activity for up to 6 h. In the present study the effect of 
nisin F, nisin A and Nisaplin® on the growth of the target strain S. aureus Xen 36 (expressed as 
bioluminescence and optical density) was recorded over 18 h.  
 
In this study, the immunomodulatory effect of partially purified nisin F was compared to partially 
purified nisin A and Nisaplin®, a purified form of nisin A. The ability of peripheral blood mononuclear 
cells (PBMCs) to produce interleukin-1β (IL-β) and IL-6, two pro-inflammatory cytokines, in the 
presence of the bacteriocins as well as an additional external stimulus, lipopolysaccharides (LPS) from 
Escherichia coli, was investigated. Lastly, the effect of different concentrations of rat serum on the 
antimicrobial effect of the bacteriocins was determined with bioluminescence imaging (BLI) using the 
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In Vivo Imaging System (IVIS® 100; Caliper Life Sciences, Hopkinton, MA) in a newly developed 
assay. 
 
Materials and methods 
Preparation of nisin F, nisin A and Nisaplin
®
 and MIC determinations 
Nisin F was produced by growing L. lactis subsp. lactis F10 [1] in De Man Rogosa Sharpe (MRS) 
broth (Biolab, Biolab Diagnostics, Midrand, South Africa) for 18 h at 30ºC. Nisin A was produced by 
growing L. lactis subsp. lactis QU51 (obtained from Prof K. Sonomoto, Kyushu University, Japan) 
under the same conditions. The two lantibiotics were concentrated from the culture-free supernatant 
with 80% saturated ammonium sulphate [28]. Nisaplin®, the commercial form of nisin A, was 
purchased from Aplin & Barret (Dorset, England), dissolved in sterile distilled water to a final 
concentration of 0.2 mg/ml and centrifuged (3000 x g, 10 min, 4ºC) to remove milk solids and 
stabilizers. The three suspensions were dialysed against sterile distilled water, concentrated by freeze-
drying and stored at -80 ºC. 
 
Freeze-dried peptides were resuspended in sterile distilled water and the antimicrobial activity of nisin 
A, nisin F and Nisaplin® determined against S. aureus strain Xen 36 (Caliper Life Sciences, 
Hopkinton, MA).  Activity was expressed in arbitrary units per ml (AU/ml). The MIC required to 
inhibit the growth of S. aureus Xen 36 was determined using a 96-well microtitre plate.  Each well 
was filled with 100 µl Mueller Hinton (MH) broth (Sigma-Aldrich, St. Louis, Mo., USA) and seeded 
with 1 x 106 CFU/ml S. aureus Xen 36.  Nisin F, nisin A and Nisaplin® were serially diluted (2-fold) 
and 100 µl added to each well.  The MIC value was expressed as the lowest concentration (AU/ml) of 
the lantibiotic required to inhibit the growth of 5 x 105 CFU/ml S. aureus Xen 36, as suggested by the 
NCCLS guidelines [24]. Total protein concentrations (mg/ml) were determined with the colorimetric 
Pierce® Bicinchoninic Acid (BCA) Protein Assay kit (Thermo Scientific, Waltham, MA, USA). 
 
The purity of nisin F, nisin A and Nisaplin® (125 AU each) was determined by tricine-sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), as described by Schägger [29], but 
modified by using 48% acrylamide/ 1.5% bis-acrylamide for the stacking gel, and 46.5% acrylamide/ 
1.5% bis-acrylamide for the separating gel.  The acrylamide/ bis-acrylamide, gel buffer, 50% glycerol 
and water were used at a ratio of 1:1:1:0.78 for the SDS separating gel and at 1:3:0:8 for the stacking 
gel. The gels were polymerized with 10% ammonium persulphate (APS) and TEMED (10:1). The 
bacteriocins were each mixed with 2x sample buffer, consisting of 0.125 M Tris (pH 6.8), 4% (w/v) 
SDS, 5% (v/v) 2-mercaptoethanol, 10% (v/v) glycerol and 0.02% (w/v) bromophenol blue, at a ratio 
of 1:1 and heated at  95°C for 5 min.  The protein samples and a low-range rainbow marker, RPN755E 
(Amersham International, United Kingdom), were separated at 180V for 4 h. Protein bands were 
visualised after silver staining, as described by Ilmén et al. [30]. 
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Effect of nisin F, nisin A and Nisaplin
®
 on leukocyte counts and functional capacity 
Whole blood from healthy male Wistar rats was collected into BD Vacutainer® K2EDTA tubes (BD 
Diagnostics, Franklin Lakes, NJ, USA), pooled and kept at room temperature. Full blood counts of 
pooled blood were measured using a Cell-Dyn hematology analyser (Cell-Dyn 3700 CS, Abbott 
Diagnostics, Santa Clara, California, USA) and HEMO, VetSoft Veterinary Software (Davis, CA, 
USA). The wells in Multiwell (BD Falcon™) tissue culture plates (BD Diagnostics) were each filled 
with 200 µl Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich, St Louis, MO, 
USA). Nisin F, A and Nisaplin®, each dissolved in 50 µl RPMI medium, was added to wells to 
correspond to final concentrations of 0.5, 1.0, 2.5 and 5.0 x MIC. Corresponding volumes of RPMI 
medium were added to control wells. To one set of tissue culture plates, 50 µl RPMI containing 
lipopolysaccharide (LPS, final concentration 1.5 µg/ml) from E. coli 0111:B4 (Sigma-Aldrich) was 
added per well to stimulate the production of cytokines. The control set received 50 µl RPMI medium 
without LPS.  All reactions were performed in triplicate. Whole blood (200 µl) was added to each well 
to a final volume of 500 µl and the plates were incubated at 37°C (98% humidity, 5% CO2) for 4 h. 
The content of each well was centrifuged (1500 x g, 10 min, 25ºC) and the supernatants collected and 
stored at -80°C. Volumes removed from the wells were replaced with equal volumes of sterile 
phosphate buffered saline (PBS). The blood cells were resuspended and cell counts determined as 
described before. The PBMC values were calculated as the sum of the monocyte and lymphocyte 
counts in each sample. Initial and final values (before and after incubation) were analysed to assess the 
net effect of changes in cell death and/or proliferation on viable PBMC count. Levels of IL-6 and IL-
1β (produced by PBMCs during incubation) in the supernatants were determined using Platinum 
Enzyme-linked Immunosorbent (ELISA) kits (eBioscience Inc., SanDiego, USA). 
 
Effect of serum on the antimicrobial activity of nisin A, nisin F and Nisaplin
®
 
Blood was collected from healthy male Wistar rats in BD Vacutainer® Plus Plastic Serum tubes (BD 
Diagnostics), pooled and centrifuged at 1500 x g (10 min, 25ºC). Media with different serum 
concentrations were prepared as follows: To obtain a 40% serum content, two parts of serum was 
added to one part 5 x MH broth (Sigma-Aldrich) and two parts sterile saline (0.85% NaCl, w/v). 
Medium containing 80% serum was prepared by adding four parts of serum to one part of 5 x MH 
broth. Medium without serum was prepared by adding one part of 5 x MH broth to four parts sterile 
saline. Wells of a microtitre plate were filled with the serum-containing media, respectively. Nisin A, 
nisin F and Nisaplin®, each suspended in sterile distilled water, were added to media to yield final 
levels of 1.0 x MIC, 2.5 x MIC and 5.0 x MIC, respectively, in total volumes of 50 µl per well. Sterile 
distilled water was used as control for the lantibiotics. Staphylococcus aureus Xen 36, cultured at 
37°C in 1 x MH broth, supplemented with 200 µg/ml kanamycin to maintain selective pressure on the 
plasmid containing the luxABCDE operon, were harvested (11300 x g, 10 min, 4°C), resuspended into 
MH broth and 50 µl added to each well to yield a final cell number of 3.8 x 105 CFU/ml. The plates 
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were incubated in the IVIS at 37°C for 18 h and bioluminescent images were recorded every 30 min 
(10 sec exposure) for 18 h. The entire size of each well was selected as one ROI and analysed with 
Living Image® software (Caliper Life Sciences).  Optical density (A600nm) readings were recorded for 
each well immediately after inoculation with S. aureus Xen 36 and after 18 h of incubation. 
 
Statistical analyses 
IL-1β and IL-6 production were analysed separately for nisin A, nisin F and Nisaplin®, using one-way 
ANOVA with Bonferroni post hoc testing (Statistica software v.10, StatSoft Inc, OK, USA). Serum 
data were analysed with the PROC GLIMMIX mixed model with time as the repeated measure (SAS 
software v. 9.3, SAS Institute Inc., USA). P-values < 0.05 were considered as significant. 
 
Results 
MIC levels of nisin A, nisin F and Nisaplin
® 
The lantibiotic preparations showed different degrees of purity, as observed with trycine SDS-PAGE 
(not shown). The specific activity of nisin A, nisin F and Nisaplin® (expressed per total protein 
content) was 766.1 AU/mg, 356.7 AU/mg and 8888.9 AU/mg, respectively, as determined against S. 
aureus Xen 36 grown in MH broth.  The MIC values against S. aureus Xen 36, were 147.7 µg/ml, 
280.0 µg/ml and 11.3 µg/ml for nisin A, nisin F and Nisaplin®, respectively. 
 
Changes in leukocyte counts and cytokine secretion 
The total white blood cell count of pooled blood was 11.7 x 106/ml. The differential cell counts were 
also within expected normal range, i.e. 9.5% neutrophils, 84.0% lymphocytes, 3.0% monocytes, 1.2% 
eosinophils and 2.3% basophils. The initial PBMC (sum total of monocyte and lymphocyte) count in 
each well was 5.3 x106/ml.  The PBMC counts remained unchanged in the presence of 0.5 x, 1.0 x, 2.5 
x and 5.0 x MIC levels of nisin A and Nisaplin®, irrespective of the absence or presence of LPS (not 
shown).  Nisin F at 0.5 x, 1.0 x and 2.5 x MIC had no effect on PBMC levels (Fig. 1).  However, the 
highest dosage of nisin F (5 x MIC) caused a significant decrease in PBMC counts (Fig. 1). At 5 x 
MIC, in the absence of LPS, PBMC counts decreased by 70% (lymphocytes by 82%).  At the same 
nisin dosage, but in the presence of LPS, the decreases in cell counts were substantially greater 
(PBMC decreased by 86.5% and lymphocytes by 90%).  
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Figure 1. Peripheral blood mononuclear cell (PBMC) counts after incubation with different 
concentrations of nisin F in the presence and absence of E. coli LPS.  -○- = spontaneous PBMCs/ml; -
□- = stimulated PBMCs/ml.  Data are presented as means ± SD of PBMCs/ml (n=3).  Values without 
common letters (a-b) differ significantly (p < 0.001). 
 
No significant differences in IL-1β and IL-6 levels were recorded in the presence of 0.5, 1.0, or 2.5 x 
MIC nisin A, nisin F or Nisaplin® when compared to the control (Fig. 2).  Nisin F showed a dose-
dependent pattern of IL-1β production.  Nisin F at 5.0 x MIC resulted in a 50.1% increase of 
spontaneous IL-1β (Fig. 2A), while no significant difference in stimulated IL-1 β or any IL-6 levels 
was seen (Fig. 2B).  The averages for stimulated production of IL-1 β in response to nisin A were 
consistently higher than the spontaneous production recorded for all MIC levels, although not 
statistically significantly (Fig. 1A).  A similar consistent effect was not observed for nisin F or 
Nisaplin®.  
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Figure 2. Spontaneous (■) and stimulated (□) production of (A) IL-1β and (B) IL-6 by peripheral 
blood mononuclear cells (PBMCs) after 4 h of incubation in the presence of 0.5, 1, 2.5 and 5 x MIC 
nisin F, nisin A and Nisaplin® . IL-1β and IL-6 production was stimulated by the addition of 1.5 µg/ml 
lipopolysaccharide (LPS) from E. coli. Data are presented as means ± SD (n=3).  Values with different 
letters (a-c) differ significantly (p < 0.05).  
 
The effect of serum on the antimicrobial activity of bacteriocins 
Ten hours of incubation in the presence of 40% (v/v) serum had no effect on the antimicrobial activity 
of nisin F at MIC values of 1.0, 2.5 and 5.0 (Fig. 3B).  Similar results were observed with nisin F 
incubated in the presence of 80% serum, except that the antimicrobial activity of 1.0 x MIC nisin F 
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decreased rapidly after 4 h of incubation (p < 0.05; Fig. 3C).  With a further 8 h of incubation in the 
presence of 40% serum, the antimicrobial activity of 1.0 x MIC nisin F declined whereas the activity 
of 2.5 x and 5.0 x MIC nisin F remained unchanged (Fig. 3B insert).  A further 8 h of incubation in the 
presence of 80% serum resulted in a decline of 2.5 x MIC nisin F activity, whereas the activity of 5.0 x 
MIC nisin F remained unaffected (p < 0.05; insert, Fig. 3C).   
 
 
 
Figure 3.  Effect of serum on the antimicrobial activity of nisin F.  Changes in the metabolic activity 
(growth) of S. aureus Xen 36 were observed by bioluminescence. A: no serum, B: 40% (v/v) serum, 
C: 80% (v/v) serum. Data are presented as means ± SD (n=3) and values without common letters (a-b) 
differ significantly (p ˂ 0.05). The insert in each graph represents the optical density readings (A600nm) 
recorded 18 h after incubation.  Significantly different values (p < 0.05) are indicated by * 
 
The activity of 1.0 x MIC nisin A was completely inhibited after 10 h of incubation in the presence of 
40% (v/v) and 80% (v/v)  serum and remained inactivated for a further 8 h (Fig. 4 B and C, 
respectively).  Higher concentrations of nisin A (2.5 x and 5.0 x MIC) were inactivated after 10 h of 
incubation in the presence of 40 % serum (Fig. 4E and H).  Incubation of 2.5 x and 5.0 x MIC nisin A 
in the presence of 80% (v/v) completely inactivated 2.5 x MIC, while 5.0 x MIC nisin A was slightly 
more resistant (Fig 4 F and I). These results were confirmed by optical density readings recorded for S. 
aureus Xen 36 (Fig. 5A).  The antimicrobial activity of 1.0 x, 2.5 x and 5.0 x MIC Nisaplin® was not 
inhibited by 40% serum (Fig. 4 B, E and H).  A slight inhibition of 5 x MIC Nisaplin® was observed in 
the presence of 80% (v/v) serum (p < 0.05, Fig. 4 I).  According to optical density readings, the growth 
of S. aureus was significantly inhibited for 18 h by all MIC dosages of Nisaplin®, irrespective of 
serum concentration (Fig 5B). 
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Figure 4. Bioluminescence of S. aureus Xen 36 incubated with different concentrations of serum (A, 
D, G: 0%; B, E, H: 40% and C, F, I: 80%) and antimicrobial proteins (A-C: 1 x MIC; D-F: 2.5 x MIC; 
G-I: 5 x MIC). Log10 values of average radiance (p/s/cm
2/sr) are shown as mean ± SD (n = 3) and 
curves without common letters (a-c) differ significantly (p < 0.05). Negative control (●), nisin A (●) 
and Nisaplin® (●). 
 
 
 
Figure 5. Optical density (A600nm) of different concentrations control ■, 1 x MIC ■, 2.5 x MIC ■ and 5 
x MIC ■ of nisin A (A) and Nisaplin® (B) incubated with S. aureus Xen 36 and different 
concentrations of rat serum (0, 40 and 80%). Values were obtained after 18 h of incubation and are 
presented as means ± SD (n = 3). Asterisks (*) indicate values with significant differences (p < 0.05). 
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When comparing the three nisin variants at 1 x MIC in media containing 80% (v/v) serum, clear 
differences in antimicrobial activity can be observed (Fig. 6).  The activity of nisin F and nisin A  was 
totally inhibited (p < 0.05), while Nisaplin® (commercially purified) was not affected. Optical density 
(A600) data obtained after 18 h confirmed results obtained by BLI (insert, Fig. 6). 
 
 
Figure 6. Bioluminescent values of nisin F (●), nisin A (●), Nisaplin® (●) and water as negative 
control (●) during incubation with S. aureus Xen36 over a period of 18 h. The proteins were added to 
a final concentration of 1 x MIC and media contained 80% serum. Curves without common letters (a-
b) differ significantly (p < 0.05). A600 values of the same samples 18 h after incubation are shown in 
the insert graph. Samples with significantly the same values (p < 0.05) are indicated with an asterisk 
(*). 
 
Discussion 
Of the three nisin preparations, Nisaplin® was the purest.  This is also evident from the low 
concentration Nisaplin® required, compared to the other preparations, to yield the same antimicrobial 
activity. 
 
Only the highest dosage of nisin F was cytotoxic to PBMCs (Fig. 1).  The decrease in cell counts was 
mainly due to lymphocyte death. In a study by Bedge et al. [16], cytotoxicity towards lymphocytes 
and neutrophils was observed after exposure of human whole blood to nisin [16]. When continuously 
administered to uninfected mice, nisin F did not cause any significant changes in relative neutrophil or 
lymphocyte counts [5]. However, the lantibiotic, in its active form, partly protected S. aureus infected 
mice against lymphocyte death.  In another study, De Pablo et al. [34] observed an increase in CD4 
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and CD8 T-lymphocytes and a decrease in B-lymphocytes in mice orally administered with Nisaplin® 
in their diet for 30 and 75 days.  The effects were, however, neutralized over time with long-term 
administration of Nisaplin® (100 days).  The phagocytic activity of peritoneal cells also increased after 
long-term administration [31].   
 
Based on lactate dehydrogenase (LDH) secretion, purified nisin Z as high as 200 µg/ml did not cause 
toxicity (through membrane permeabilisation) to human PBMCs [17].  The same concentration of 
gallidermin, on the other hand, caused roughly 40% cytotoxicity.  The authors did not assess leukocyte 
viability.  Nisin showed an immunostimulatory effect through head kidney macrophages after i.p. 
administration to fish [18].  The purity of the nisin used in previous studies are however not clear.  An 
exception is an in vivo toxicity study done by Gupta et al. [15] where RP-HPLC purified nisin (free of 
milk solids and high salt concentration usually found in commercial versions of nisin) was applied as a 
vaginal microbicide in rats.  No toxic effect was observed. In the case of toxicity, the host will often 
break down foreign peptides into nontoxic amino acids that can be metabolized [32].  Nisin [33], 
pediocin [34] and peptide AS-48 [35] also showed an immunogenic effect in antibody studies.   
 
Recently, nisin Z was proposed to be similar in action as the natural host-defense peptide (HDP) and 
synthetic innate defense peptide (IDR) [17].  Nisin was able to enhance innate immunity both ex vivo 
in human PBMCs as well as in vivo in mice.  Nisin Z (50 µg/ml), and not Pep5 or gallidermin, caused 
human PBMCs to produce the cytokines monocyte chemoattractant protein-1 (MCP-1), gro-α and IL-8 
in a dose-dependent manner after 24 h incubation.  In the prescence of 2 ng/ml LPS from 
Pseudomonas aeruginosa, 50 µg/ml nisin Z caused a significant reduction in production of the pro-
inflammatory cytokine, TNF-α, by PBMCs after 24 h incubation.  More significantly it was 
determined that stimulation of IL-6 production together with various pathways modulates the immune 
system.  When administrated 1 h post-infection, these immunomodulatory properties offered partial 
protection against infection by Gram-negative organisms such as E. coli and Salmonella thyphimurium 
in mice, even though nisin Z is not active against these organisms.  In another study, the bacteriocin 
CBT-SL5 also suppressed IL-8 production in human keratinocytes exposed to Propionibacterium 
acnes [36].  In our case, cell death was preceded by a burst of IL-1β production (Fig. 2), which is also 
a pro-inflammatory cytokine.  This might suggest that nisin F has a different mechanism of action, 
compared to nisin Z, although conditions differed greatly from this study. 
 
The inhibitory effect serum has on the antimicrobial activity of nisin F and nisin A (Figs 3-6) is 
contradicting to the study done by Ghobrial et al. [37] where the MIC of the lantibiotic MU114 against 
S. aureus decreased from 6.4 µg/ml to 1.6 µg/ml in media containing 25% and 50% human serum. 
Purified nisin A (Nisaplin®) was less affected by serum.  MIC dosages are usually determined based 
on visible changes recorded in bacterial growth. Because the IVIS used in this study is based on 
bioluminescence (metabolic activity), it is more accurate.  Even though bacterial cells might not be 
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visible with the eye, metabolic activity will produce a bioluminescent signal that can be detected with 
the IVIS.  This might explain the slight increase in bioluminescence observed at the end of incubation 
(Fig. 3, 4, 6) even though all dosages were equal to or higher than 1 x MIC.  These facts further 
illustrate the sensitivity of the assay developed here.  Binding and inactivation of nisin F by serum 
could limit the in vivo therapeutic application of the lantibiotic.  Future studies could include 
development of ways to overcome this problem. 
 
From bioluminescent results we can conclude that preparation (as seen between Nisaplin® and the 
semi-purified nisin A and F) plays a significant role in PB in serum (Fig. 6).  However, cytotoxicity 
was more dependent on the type of nisin (Fig. 1).  The semi-purified form of nisin F, which was used 
in all our previous studies [4,5,38], showed similar SDS-PAGE separation profiles and antimicrobial 
activity in rat serum (Fig. 6) as nisin A.  Thus, further purification of nisin F might decrease PB and 
antigenicity of the lantibiotic, allowing more effective in vivo application. 
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General Discussion and Conclusions 
 
The global pharmaceutical market experienced rapid growth over the last ten years and was estimated 
at €614,583 million ($855,500 million) in 2011 (EFPIA 2012). Although the annual growth rate of 
research and development (R&D) in leading countries like Europe and the United States of America 
suffered a decrease of 81.8 and 75.9%, respectively, over the last ten years (EFPIA), South Africa has 
been ranked as one of seventeen “Pharmerging” countries with high-growth pharmaceutical markets 
(IMS 2011). Unfortunately this economic asset also comes with several drawbacks. The increase in 
novel antibiotics leads to over-subscription of antibiotics by medical practitioners and that leads to 
increased antibiotic resistant pathogens, which in turn lead to an even greater need for novel 
antibiotics - in essence, the start of a vicious cycle. 
 
Antimicrobial peptides like nisin F have various attributes rendering them attractive for use as 
pharmaceuticals. Because they are small, they can reach infected areas more easily and increase 
possibilities for drug engineering. They also show high specificity and potency. Peptide 
pharmaceuticals are widely used in fields like oncology, diagnostics, diabetes, obesity, arthritis, 
cardiovascular disease and central nervous system disorders (Ayoub and Scheidegger 2006). One 
major disadvantage of such peptides is the short half-life and rapid degradation by proteolytic enzymes 
like aminopeptidases and carboxypeptidases, followed by endopeptidases cleaving to specific sites 
within the peptide (Rink et al. 2010). 
 
From in vitro work in this study, it was determined that the lantibiotic nisin F has the best activity 
against S. aureus Xen 36, compared to other pathogens in our bioluminescent culture collection. After 
exploring different in vivo routes of infection (i.g., i.p., i.m., i.v.), we concluded that intraperitoneal 
administration was the most effective in establishing systemic infection and treatment (Chapter 3, 
Brand et al. 2011). Dosages for infection and treatment applied in subsequent studies were also 
optimized. C57BL/6 mice were used to determine the in vivo antimicrobial effect of nisin F against S. 
aureus Xen 36 infection. Results showed that nisin F suppressed S. aureus growth in the peritoneal 
cavity for at least 15 min (Chapter 4, Brand et al. 2010). In addition, no abnormalities were observed 
in histological analysis of the hearts, lungs, livers, spleens, kidneys and intestinal organs of the mice. 
 
The in vivo stability of nisin F was further examined in BALB/c mice intraperitoneally infected with S. 
aureus Xen36 (Chapter 5). Four hours after infection, mice were surgically implanted with Alzet 
osmotic minipumps filled with active and inactive nisin F. Nisin F-coated polyethylene tubing was 
connected to each minipump and inserted through an incision in the peritoneum of the mouse to ensure 
the delivery of nisin F inside the peritoneal cavity and its uptake into the bloodstream. Infection was 
monitored with bioluminescent imaging (BLI) for seven days, and no significant differences could be 
recorded between groups treated with active and inactive nisin F. Differential blood counts 
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(specifically neutrophils and lymphocytes) suggest that nisin F might significantly enhance the 
inflammatory response in the presence of a pathogen. Similarly, but at much lower magnitude, nisin F 
also caused an increase in IL-6 and decrease in IL-10 levels 24 h after initiation of treatment in the 
absence of an added pathogen. Taken together, these data suggest that while the lantibiotic itself does 
not cause an inappropriate immune response or intolerance when administered in the absence of 
bacterial infection, it may indeed have immune boosting functions in the presence of bacterial 
infection. 
 
The interpretation of the in vivo cytokine response (Chapter 5) is further substantiated by the results of 
the ex vivo assay in Chapter 6. PBMCs incubated with nisin F produced IL-1β in a dose-dependent 
way. Cytotoxicity to leukocytes (especially lymphocytes) observed after exposure to the highest 
concentration (5 x MIC) of nisin F could be overcome through further purification of the peptide. 
Cells cultured with nisin F and an added pathogen, E. coli LPS, were still able to elicit an immune 
response similar to controls (without nisin F). 
 
A clear difference was observed between the purity of semi-purified extracts of nisin F and nisin A 
when compared to Nisaplin®, a commercial form of nisin A (Chapter 6). These results were confirmed 
when the three above-mentioned proteins were incubated with S. aureus Xen 36 and media containing 
three different serum concentrations (0%, 40% and 80%). The metabolic activity of S. aureus in the 
presence of serum and different dosages of the proteins (1 x MIC, 2.5 x MIC and 5 x MIC) was 
measured with a bioluminescent assay. The results were confirmed with optical density measurements. 
Serum tolerance was significantly less in semi-purified nisin F and nisin A, compared to Nisaplin®. 
Because they are foreign to the animal/patient’s body, peptides are often degraded or lysed (Rink et al. 
2010). The combination of bacteriocins and other treatments like pulsed electric fields, high 
hydrostatic pressure and organic acids, enhances potency of the bacteriocins and treatment of Gram-
negative bacteria (Taylor et al. 1985; Mazzotta and Montville 1997; De Martinis et al.1997). 
Nanotechnology can be applied to protect peptides or antibiotics inside nanoparticles or polymer 
coatings that will enable slow release of the compounds (Guillaume et al. 2012) FDA- approved 
water-soluble polymers can be used and manipulated for sustained release. 
 
This was the first time the in vivo antimicrobial effect and stability of nisin F was monitored in the 
bloodstream. After determining a model for systemic infection and treatment, we established that nisin 
F controlled S. aureus growth in the peritoneal cavity for at least 15 min after a single administration. 
However, after administration of the peptide for seven days, active nisin F had the same effect on S. 
aureus growth as inactive nisin F, according to bioluminescence. Blood counts of infected mice 
showed that active nisin F exerted protection against lymphocyte death. The immune boosting effect 
of nisin F in terms of IL-6 and IL-10 when administered in the absence of infection shows that the 
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peptide might act in an immunomodulatory way to aid its host against infection. Future studies could 
involve further purification of the peptide, followed by novel application methods. 
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